Polycystic Ovary Syndrome

🏷

Classifications

Harrison's Chapter

◆

Subtypes

2

Lean / nonobese PCOS

PCOS occurring without obesity. This stratum is useful for separating intrinsic, obesity-independent insulin signaling defects and neuroendocrine/ovarian androgen mechanisms from adiposity-amplified metabolic dysfunction. Lean PCOS is still heterogeneous; some lean affected groups may have normal insulin sensitivity.

Show evidence (2 references)

PMID:1397698 SUPPORT Human Clinical

"These defects in insulin action appear to represent intrinsic abnormalities that are independent of obesity, metabolic derangements, body fat topography, and sex hormone levels."

Euglycemic clamp and adipocyte data support an obesity-independent intrinsic insulin-action defect relevant to nonobese PCOS.

PMID:23065822 PARTIAL Other

"There is general agreement that obese women with PCOS are insulin resistant, but some groups of lean affected women may have normal insulin sensitivity."

The review supports subtype heterogeneity within lean PCOS, so lean status should not be modeled as synonymous with insulin resistance.

Obese / adiposity-amplified PCOS

PCOS with overweight, obesity, or abdominal/visceral adiposity. This stratum emphasizes adiposity-driven insulin resistance, hyperinsulinemia, lower SHBG, and inflammatory amplification of androgen excess and anovulation.

Show evidence (2 references)

PMID:12080440 SUPPORT Other

"Obesity, particularly the abdominal phenotype, may be partly responsible for insulin resistance and associated hyperinsulinemia in women with PCOS."

Review evidence supports abdominal obesity as an amplifier of insulin resistance and hyperinsulinemia in PCOS.

PMID:12080440 SUPPORT Other

"Irrespective of the pathogenetic mechanism involved, obese PCOS women have more severe hyperandrogenism and related clinical features (such as hirsutism, menstrual abnormalities and anovulation) than normal-weight PCOS women."

The subtype description is supported by evidence that obesity worsens androgenic and reproductive PCOS features.

◈

Mechanistic Hypotheses

4

Androgen-First Feedback Model

androgen_first_feedback_model ALTERNATIVE Lean PCOS Obese PCOS

Intrinsic ovarian/adrenal androgen excess, potentially reinforced by heightened LH action and theca-cell steroidogenic machinery, is the initiating lesion. Androgen excess then promotes insulin resistance and hyperinsulinemia, disrupts hypothalamic steroid feedback, and contributes to visceral adiposity, closing an androgen-insulin-adiposity feedback loop.

Pathograph links

Hyperandrogenism -> Intrinsic Post-Receptor Insulin Signaling Defect INDIRECT KNOWN INTERMEDIATES Androgen excess can worsen insulin resistance and hyperinsulinemia, creating a self-perpetuating endocrine-metabolic loop. Intermediates: androgen receptor effects in skeletal muscle and adipose tissue; compensatory or androgen-augmented hyperinsulinemia

Hyperandrogenism -> Adiposity-Amplified Insulin Resistance INDIRECT KNOWN INTERMEDIATES Hyperandrogenism favors visceral adiposity and adverse adipose signaling, which can amplify insulin resistance in obese PCOS. Intermediates: visceral fat deposition; adipokine and free-fatty-acid changes

Hyperandrogenism -> Hypothalamic-Pituitary Dysregulation INDIRECT KNOWN INTERMEDIATES Ongoing androgen excess helps sustain abnormal hypothalamic sensitivity to estradiol/progesterone negative feedback, maintaining rapid LH/GnRH pulse secretion. Intermediates: impaired ovarian steroid negative feedback

Hyperandrogenism -> Ovulatory Dysfunction INDIRECT KNOWN INTERMEDIATES Elevated androgen exposure disrupts follicle maturation and contributes to anovulation. Intermediates: follicular arrest; impaired dominant follicle selection

Adiposity-Amplified Insulin Resistance -> Chronic Low-Grade Inflammation INDIRECT KNOWN INTERMEDIATES Visceral adiposity and insulin resistance contribute to the inflammatory state shared by PCOS, obesity, type 2 diabetes, and cardiovascular disease. Intermediates: adipokine dysregulation; inflammatory cytokine production

Deep research

OpenScientist citations 33 citations 2026-06-06T23:47:40.676815

Show evidence (2 references)

PMID:38152131 SUPPORT Other

"Compelling evidence suggests that hyperandrogenism is not just a primary feature of PCOS. Instead, it may be a causative factor for this condition."

This review explicitly frames androgen excess as a possible causal driver, supporting the androgen-first hypothesis group.

PMID:35356614 SUPPORT Other

"However, the overexposure of androgen has direct and specific influence on the development of insulin resistance."

Supports the androgen-to-insulin-resistance arm of the proposed feedback model.

Insulin/Hyperinsulinemia-First Model

insulin_hyperinsulinemia_first_model ALTERNATIVE Lean PCOS Obese PCOS

Primary insulin resistance or primary hyperinsulinemia initiates the endocrine-metabolic loop. High insulin acts as a co-gonadotropin in the ovary and lowers hepatic SHBG, increasing bioactive androgen exposure; the resulting hyperandrogenism can then worsen insulin resistance and adiposity.

Pathograph links

Intrinsic Post-Receptor Insulin Signaling Defect -> Hyperandrogenism INDIRECT KNOWN INTERMEDIATES Hyperinsulinemia arising from impaired insulin signaling can act as a co-gonadotropin and increase bioactive androgen exposure. Intermediates: compensatory hyperinsulinemia; ovarian insulin receptor signaling; hepatic SHBG suppression

Intrinsic Post-Receptor Insulin Signaling Defect -> Ovulatory Dysfunction INDIRECT KNOWN INTERMEDIATES Hyperinsulinemia and androgen amplification contribute to follicular arrest and anovulation. Intermediates: increased bioactive androgens; altered pituitary hormone balance

Adiposity-Amplified Insulin Resistance -> Hyperandrogenism INDIRECT KNOWN INTERMEDIATES Obesity-related hyperinsulinemia increases ovarian androgen synthesis and lowers SHBG, raising bioactive androgen exposure. Intermediates: obesity-related hyperinsulinemia; ovarian insulin co-gonadotropin activity; decreased hepatic SHBG synthesis

Adiposity-Amplified Insulin Resistance -> Chronic Low-Grade Inflammation INDIRECT KNOWN INTERMEDIATES Visceral adiposity and insulin resistance contribute to the inflammatory state shared by PCOS, obesity, type 2 diabetes, and cardiovascular disease. Intermediates: adipokine dysregulation; inflammatory cytokine production

Deep research

OpenScientist citations 30 citations 2026-06-04T00:54:15.281185

Show evidence (2 references)

PMID:40013621 SUPPORT Other

"Hyperinsulinemia (i.e., elevated insulin without hypoglycemia) is a common metabolic feature of PCOS that worsens its reproductive symptoms by exacerbating pituitary hormone imbalances and increasing levels of bioactive androgens."

Supports hyperinsulinemia as an upstream amplifier of pituitary imbalance and bioactive androgen excess.

PMID:23065822 SUPPORT Other

"Insulin functions as a co-gonadotropin through its cognate receptor to modulate ovarian steroidogenesis."

Supports the ovarian steroidogenesis route by which hyperinsulinemia can increase androgen production.

Neuroendocrine LH-Pulse Model

neuroendocrine_lh_first_model ALTERNATIVE Lean PCOS Obese PCOS

Impaired hypothalamic-pituitary sensitivity to ovarian steroid negative feedback maintains rapid LH/GnRH pulse secretion. Elevated LH signaling then drives theca-cell androgen biosynthesis, while androgen excess further impairs steroid feedback and can secondarily worsen insulin resistance.

Pathograph links

Hyperandrogenism -> Hypothalamic-Pituitary Dysregulation INDIRECT KNOWN INTERMEDIATES Ongoing androgen excess helps sustain abnormal hypothalamic sensitivity to estradiol/progesterone negative feedback, maintaining rapid LH/GnRH pulse secretion. Intermediates: impaired ovarian steroid negative feedback

Hyperandrogenism -> Ovulatory Dysfunction INDIRECT KNOWN INTERMEDIATES Elevated androgen exposure disrupts follicle maturation and contributes to anovulation. Intermediates: follicular arrest; impaired dominant follicle selection

Hypothalamic-Pituitary Dysregulation -> Hyperandrogenism INDIRECT KNOWN INTERMEDIATES Rapid LH/GnRH pulse secretion increases LH action on ovarian theca cells, promoting androgen biosynthesis. Intermediates: increased LH action at theca-cell LHCGR; CYP17A1-mediated androgen biosynthesis

Show evidence (2 references)

PMID:11095431 SUPPORT Human Clinical

"The majority of patients have elevated LH levels in plasma and a persistent rapid frequency of LH (GnRH) pulse secretion, the mechanisms of which are unclear."

Supports the upstream neuroendocrine abnormality represented by this hypothesis group.

PMID:11095431 SUPPORT Human Clinical

"These results suggest that although the elevated LH pulse frequency in PCOS may in part reflect impaired sensitivity to E2 and P, continuing actions of hyperandrogenemia are important for sustaining the abnormal hypothalamic sensitivity to feedback inhibition by ovarian steroids."

Supports the feedback component connecting androgen excess and persistent hypothalamic-pituitary dysregulation.

Population-Stratified Mechanistic Heterogeneity

population_stratified_mechanistic_heterogeneity EMERGING

PCOS pathophysiology exhibits significant population-specific molecular phenotypes. East Asian populations show a predominant enrichment of metabolic dysregulation-associated pathways (insulin receptor signaling, GLUT4 translocation, metabolic syndrome), whereas European populations exhibit a stronger inflammatory and immune-related signature (NF-kB signaling, innate immunity, and interleukin/cytokine and inflammasome pathways). These population-specific mechanistic differences may drive differential therapeutic responsiveness and clinical phenotypes across ancestry groups.

Show evidence (2 references)

PMID:42365073 SUPPORT Computational

"our analyses reveal a predominant enrichment of metabolic dysregulation-associated pathways in East Asian PCOS, whereas European PCOS exhibits a stronger inflammatory and immune-related signature"

Population-aware gene prioritization framework combining regulatory genomics, QTLs, and protein networks reveals distinct pathway enrichment patterns: East Asian PCOS driven by metabolic dysfunction, European PCOS by inflammation/immunity, with implications for subtype-specific therapeutics.

PMID:42365073 SUPPORT Computational

"These population-specific molecular phenotypes were further supported by transcriptomic data from PCOS patient samples"

Patient transcriptome data validate population-stratified pathway enrichment, confirming mechanistic divergence between East Asian and European PCOS cohorts rather than technical artifacts.

?

Discussions and Knowledge Gaps

4

In which PCOS patient strata is androgen excess, insulin resistance or hyperinsulinemia, adiposity, or hypothalamic-pituitary dysregulation the initiating event rather than an amplifier of an already established endocrine-metabolic cycle?

KNOWLEDGE GAP OPEN gap_pcos_causal_hierarchy_by_adiposity

Attached to

pathophysiology#Hyperandrogenism pathophysiology#Intrinsic Post-Receptor Insulin Signaling Defect pathophysiology#Adiposity-Amplified Insulin Resistance pathophysiology#Hypothalamic-Pituitary Dysregulation

Current evidence supports bidirectional reinforcement among androgen excess, hyperinsulinemia/insulin resistance, and adiposity, but it does not establish a single causal sequence that applies across lean and obese PCOS. The entry therefore models three competing or superimposed hypothesis groups and annotates causal edges by subgroup.

Show evidence (2 references)

PMID:38637590 SUPPORT Other

"Treatment remains ad hoc owing to limited understanding of underlying mechanisms, highlighting the need for research delineating the aetiology and pathophysiology of the syndrome."

The Disease Primer frames unresolved PCOS mechanisms as a research need, supporting the explicit knowledge-gap discussion.

PMID:40013621 SUPPORT Other

"Considering the heterogeneous nature of PCOS, it is improbable that its metabolic characteristics always follow the same progression."

Supports subtype-specific causal hierarchy rather than a single universal insulin-resistance sequence.

Granulosa cell apoptosis is a primary driver of follicular arrest and impaired oocyte maturation in PCOS, but the upstream triggers of that apoptosis remain unclear. Is a PCSK9 -> lipid metabolism abnormality -> AMPK/GSK-3beta -> apoptosis cascade a primary, translatable mechanism in human PCOS, and how does it relate to the parallel ferroptosis-autophagy and ER/oxidative-stress death programs already described in granulosa cells?

KNOWLEDGE GAP OPEN gap_pcos_granulosa_apoptosis_pcsk9

Attached to

pathophysiology#Granulosa Cell Ferroptosis-Autophagy Crosstalk pathophysiology#Ovulatory Dysfunction pathophysiology#Chronic Low-Grade Inflammation

Granulosa cell death is recognized as one of the primary factors impairing follicular growth, development, and oocyte maturation in PCOS, yet its upstream pathological triggers have been poorly defined. Teng et al. (2026) propose a specific cascade in which elevated proprotein convertase subtilisin/kexin type-9 (PCSK9) drives lipid metabolism abnormalities that activate AMP-activated protein kinase (AMPK) and glycogen synthase kinase 3beta (GSK-3beta) within follicles, triggering granulosa cell apoptosis and impairing ovarian function. Several questions remain unresolved. First, the cascade was established in PCOS model mice and primary follicles, so whether elevated PCSK9 is a primary driver in human PCOS rather than a species- or model-specific finding is unknown. Second, the proximal mechanism by which PCSK9-driven lipid abnormalities impair granulosa cell survival (intracellular lipid-droplet accumulation versus altered membrane lipid composition versus lipotoxic oxidative stress) is undefined. Third, it is unclear whether AMPK/GSK-3beta is the dominant death pathway or whether it operates in parallel with the previously modeled ferroptosis-autophagy crosstalk and ER/oxidative-stress programs that also drive granulosa cell loss. Resolving the relative contribution and translatability of these death pathways would clarify whether PCSK9 inhibition is a viable PCOS-directed therapeutic target.

Proposed experiments

PCSK9-lipid-AMPK/GSK-3beta apoptosis cascade in human granulosa cells with model comparison

mechanistic intervention study with human-tissue and animal-model arms

exp_pcos_pcsk9_granulosa_apoptosis_human_vs_model

Compare PCSK9 expression, follicular-fluid and intracellular lipid profiles, AMPK/GSK-3beta activation status, and apoptosis markers in granulosa cells from PCOS patients versus controls, alongside PCSK9 gain- and loss-of-function in primary granulosa cells and PCOS model mice. Use pharmacologic PCSK9 inhibition and AMPK/GSK-3beta blockade to test whether interrupting the cascade rescues granulosa cell survival and follicular development, and assay ferroptosis/autophagy and ER-stress markers in parallel to determine pathway dominance versus redundancy.

Readouts

Granulosa cell apoptosis after PCSK9 modulation

pathophysiology#Granulosa Cell Ferroptosis-Autophagy Crosstalk

Quantify granulosa cell apoptosis (caspase-3 activity, TUNEL, annexin V) in response to PCSK9 overexpression, PCSK9 inhibition, and AMPK/GSK-3beta blockade in human and mouse granulosa cells.

TUNEL apoptosis assay caspase-3 activity assay

Direction: POSITIVE

Lipid handling and AMPK/GSK-3beta signaling

pathophysiology#Granulosa Cell Ferroptosis-Autophagy Crosstalk

Measure intracellular lipid-droplet content, membrane lipid composition, and phosphorylation of AMPK and GSK-3beta to map the proximal lipotoxic-to-apoptotic signaling link.

intracellular lipid quantification phospho-protein immunoblotting

Direction: POSITIVE

Follicular development and ovulatory rescue

pathophysiology#Ovulatory Dysfunction

Assess antral follicle counts, dominant follicle selection, ovulation rate, and oocyte maturation after cascade interruption in PCOS model mice to test functional reversibility.

ovarian histomorphometry oocyte maturation scoring

Direction: NEGATIVE

Decision criterion

The PCSK9-lipid-AMPK/GSK-3beta cascade is supported as a primary, translatable apoptosis driver if elevated PCSK9 and AMPK/GSK-3beta activation are reproducibly associated with increased granulosa cell apoptosis in human PCOS tissue, PCSK9 or AMPK/GSK-3beta inhibition reduces apoptosis and restores follicular development in models, and the effect is at least partially independent of the ferroptosis-autophagy and ER-stress death programs.

Would support

pathophysiology#Granulosa Cell Ferroptosis-Autophagy Crosstalk pathophysiology#Ovulatory Dysfunction

Show evidence (2 references)

PMID:42093080 SUPPORT Model Organism

"The mechanism underlying granulosa cell apoptosis in polycystic ovary syndrome remains unclear."

Directly states the unresolved mechanism that this knowledge-gap discussion captures.

PMID:42093080 SUPPORT Model Organism

"Results demonstrated that elevated PCSK9 levels induce lipid metabolism abnormalities in PCOS mice, subsequently activating AMP-activated protein kinase and glycogen synthase kinase 3β within follicles."

Establishes the proposed PCSK9 -> lipid abnormality -> AMPK/GSK-3beta cascade in PCOS model mice that the gap and proposed experiments interrogate for human translatability.

Given the distinct population-stratified molecular phenotypes of PCOS (metabolic-dominant in East Asian populations, inflammatory-dominant in European populations), are currently approved therapies (metformin, oral contraceptives, spironolactone) equally effective across ancestry groups? Should therapeutic prioritization differ by population-specific mechanism, with metabolic pathway inhibitors favored in East Asian PCOS and immunomodulatory or anti-inflammatory agents in European PCOS?

KNOWLEDGE GAP OPEN gap_pcos_population_specific_therapeutics

Attached to

pathophysiology#Intrinsic Post-Receptor Insulin Signaling Defect pathophysiology#Adiposity-Amplified Insulin Resistance pathophysiology#Chronic Low-Grade Inflammation

Population-stratified mechanistic analyses reveal that East Asian PCOS is enriched for metabolic dysregulation pathways while European PCOS exhibits stronger inflammatory and immune signatures. The heterogeneous molecular architecture suggests that therapeutic responses may vary by ancestry, yet current PCOS treatment guidelines do not account for mechanistic diversity. Whether therapies targeting the predominant mechanism in each population (e.g., metabolic pathway inhibitors for East Asian PCOS, anti-inflammatory agents for European PCOS) would improve clinical outcomes relative to universal treatment remains untested.

Show evidence (1 reference)

PMID:42365073 SUPPORT Computational

"integration of genetic evidence with a network-based approach enabled the identification of druggable targets lacking direct genetic cues"

Network-based gene prioritization strategy identifies population-specific druggable targets and therapeutic candidates that would not emerge from genetic associations alone, laying a foundation for ancestry-informed precision therapeutics.

The PCSK9 -> lipid metabolism abnormality -> AMPK/GSK-3beta -> granulosa cell apoptosis cascade was established in PCOS model mice and primary mouse follicles. Is elevated PCSK9 a primary driver of granulosa cell apoptosis in human PCOS, or is its causal, apoptosis-initiating role a species- or model-specific finding that does not translate to human follicular biology?

HUMAN MODEL MISMATCH OPEN gap_pcos_pcsk9_granulosa_mouse_model_mismatch

Attached to

pathophysiology#Granulosa Cell Ferroptosis-Autophagy Crosstalk pathophysiology#Ovulatory Dysfunction

Granulosa cell apoptosis is recognized as a primary factor impairing follicular growth, oocyte maturation, and fertility in PCOS, but its upstream triggers remain unclear. Teng et al. (2026) provide mechanistic evidence in PCOS model mice that elevated proprotein convertase subtilisin/ kexin type-9 (PCSK9) induces lipid metabolism abnormalities that activate AMP-activated protein kinase (AMPK) and glycogen synthase kinase 3beta (GSK-3beta) within follicles, triggering granulosa cell apoptosis. This is not a generic knowledge gap in which evidence is absent; rather, positive mechanistic evidence exists in a mouse model and the open question is its translational validity to human disease. The mismatch is mechanistically meaningful because PCSK9, hepatic and ovarian lipid handling, and androgen-driven lipotoxicity differ substantially between rodents and humans, so a cascade that is causal and apoptosis-initiating in mouse follicles could be absent, secondary, or merely correlative in human PCOS ovaries. Resolving whether elevated PCSK9 is a primary human driver is a prerequisite for treating PCSK9 inhibition as a PCOS-directed therapeutic target rather than a mouse-specific observation.

Proposed experiments

PCSK9 and granulosa cell apoptosis in human PCOS follicles

human granulosa cell apoptosis and follicular-fluid PCSK9 profiling study

exp_pcos_pcsk9_human_granulosa_apoptosis

Measure PCSK9 levels in follicular fluid and granulosa cells from PCOS patients versus matched controls undergoing assisted reproduction, and correlate with intrafollicular lipid profiles, AMPK and GSK-3beta phosphorylation status, and granulosa cell apoptosis markers. Elevated PCSK9 reproducibly tracking with AMPK/GSK-3beta activation and increased apoptosis in human PCOS tissue would support translational validity of the mouse-derived cascade; absence of this association would indicate a model-specific finding.

Model systems

Human PCOS patient-derived granulosa cells

Granulosa cells and matched follicular fluid recovered at oocyte retrieval from PCOS patients and ovulatory controls, preserving human ovarian lipid-handling and apoptosis biology.

PRIMARY CELL CULTURE

PCSK9 gain- and loss-of-function in human granulosa cell apoptosis assay

human granulosa cell apoptosis assay

exp_pcos_pcsk9_human_granulosa_perturbation

In primary human granulosa cells, test whether PCSK9 overexpression induces, and PCSK9 inhibition or AMPK/GSK-3beta blockade rescues, lipid accumulation and apoptosis. Demonstrating that PCSK9 manipulation causally raises and lowers human granulosa cell apoptosis through the AMPK/GSK-3beta axis would establish the cascade as a primary, translatable human mechanism rather than a mouse-restricted one.

Model systems

Primary human granulosa cell culture

Cultured primary granulosa cells from human ovarian follicles used for PCSK9 gain- and loss-of-function manipulation and apoptosis readouts.

PRIMARY CELL CULTURE

Seeded from PMID:42093080 — Lipid metabolism abnormalities induced by elevated PCSK9 in polycystic ovary syndrome mice lead to ovarian granulosa cell apoptosis via AMPK and GSK-3β. Complements the same-source KNOWLEDGE_GAP discussion gap_pcos_granulosa_apoptosis_pcsk9; this entry adds the HUMAN_MODEL_MISMATCH translational framing and proposed human experiments.

⚙

Pathophysiology

12

Hyperandrogenism

Excess androgen production from ovarian theca cells and adrenal glands leads to hirsutism, acne, and alopecia. Elevated LH stimulates theca cell androgen production.

Androgen-First Feedback Model Neuroendocrine LH-Pulse Model

Androgen Biosynthesis GO:0006702

Downstream

Intrinsic Post-Receptor Insulin Signaling Defect Androgen excess can worsen insulin resistance and hyperinsulinemia, creating a self-perpetuating endocrine-metabolic loop.

Adiposity-Amplified Insulin Resistance Hyperandrogenism favors visceral adiposity and adverse adipose signaling, which can amplify insulin resistance in obese PCOS.

Hypothalamic-Pituitary Dysregulation Ongoing androgen excess helps sustain abnormal hypothalamic sensitivity to estradiol/progesterone negative feedback, maintaining rapid LH/GnRH pulse secretion.

Ovulatory Dysfunction Elevated androgen exposure disrupts follicle maturation and contributes to anovulation.

Show evidence (4 references)

PMID:38152131 SUPPORT Other

"Compelling evidence suggests that hyperandrogenism is not just a primary feature of PCOS. Instead, it may be a causative factor for this condition."

This review establishes hyperandrogenism as potentially causative rather than merely symptomatic in PCOS pathophysiology.

PMID:24014605 SUPPORT Human Clinical

"LHCGR and 17α-hydroxylase/17-20-lyase (CYP17A1) protein levels are increased in polycystic ovaries (PCOs)."

Direct evidence of increased androgen biosynthetic machinery (CYP17A1) in PCOS ovaries, supporting intrinsic theca cell abnormality.

PMID:24014605 SUPPORT Human Clinical

"A significant increase in the intensity of immunostaining for CYP17A1 was identified in antral follicles in sections of PCO compared with ovaries from normal women (P = 0.04)."

Quantitative demonstration of elevated CYP17A1 protein in polycystic ovaries compared to controls.

+ 1 more reference

Hypothalamic-Pituitary Dysregulation

Impaired hypothalamic-pituitary sensitivity to estradiol and progesterone negative feedback maintains rapid LH/GnRH pulse secretion. Elevated LH then stimulates theca-cell androgen biosynthesis, while hyperandrogenism can sustain the abnormal feedback state.

Neuroendocrine LH-Pulse Model

Increased Luteinizing Hormone Secretion GO:0032275 ↑ INCREASED

Downstream

Hyperandrogenism Rapid LH/GnRH pulse secretion increases LH action on ovarian theca cells, promoting androgen biosynthesis.

Show evidence (2 references)

PMID:11095431 SUPPORT Human Clinical

"The majority of patients have elevated LH levels in plasma and a persistent rapid frequency of LH (GnRH) pulse secretion, the mechanisms of which are unclear."

Human endocrine profiling supports elevated LH and rapid LH/GnRH pulse secretion as a PCOS pathophysiology node.

PMID:11095431 SUPPORT Human Clinical

"These results suggest that although the elevated LH pulse frequency in PCOS may in part reflect impaired sensitivity to E2 and P, continuing actions of hyperandrogenemia are important for sustaining the abnormal hypothalamic sensitivity to feedback inhibition by ovarian steroids."

Antiandrogen intervention restoring feedback sensitivity supports a bidirectional link between hyperandrogenism and hypothalamic-pituitary dysregulation.

Intrinsic Post-Receptor Insulin Signaling Defect

PCOS-associated insulin resistance can reflect an intrinsic post-binding or post-receptor defect in insulin signaling that is independent of obesity. Defective insulin receptor or IRS-associated signaling decreases metabolic glucose disposal while ovarian steroidogenic actions of insulin may remain active, allowing insulin and LH to amplify androgen production.

Insulin/Hyperinsulinemia-First Model

Insulin Signaling GO:0008286 ↓ DECREASED

Downstream

Hyperandrogenism Hyperinsulinemia arising from impaired insulin signaling can act as a co-gonadotropin and increase bioactive androgen exposure.

Ovulatory Dysfunction Hyperinsulinemia and androgen amplification contribute to follicular arrest and anovulation.

Show evidence (6 references)

PMID:1397698 SUPPORT Human Clinical

"Because insulin binding was not changed, we conclude that the major lesion causing insulin resistance in PCO is a striking decrease in insulin sensitivity secondary to a defect in the insulin receptor and/or postreceptor signal transduction."

Human clamp and adipocyte data support a post-binding/post-receptor insulin signaling defect as an intrinsic PCOS mechanism.

PMID:11440917 SUPPORT Human Clinical

"We conclude that there is a physiologically relevant defect in insulin receptor signaling in PCOS that is independent of obesity and type 2 diabetes mellitus."

Skeletal muscle signaling data support an obesity-independent insulin receptor signaling defect in PCOS.

PMID:23065822 SUPPORT Other

"There is a post-binding defect in receptor signaling likely due to increased receptor and insulin receptor substrate-1 serine phosphorylation that selectively affects metabolic but not mitogenic pathways in classic insulin target tissues and in the ovary."

Review evidence supports selective metabolic insulin resistance with preserved non-metabolic insulin signaling branches.

+ 3 more references

Adiposity-Amplified Insulin Resistance

Abdominal or visceral adiposity amplifies insulin resistance and hyperinsulinemia in susceptible PCOS patients. This pathway separates obesity-related hepatic/adipose insulin resistance from intrinsic lean-PCOS insulin signaling defects and explains why obesity worsens androgenic and reproductive features without being required for PCOS.

Androgen-First Feedback Model Insulin/Hyperinsulinemia-First Model

Insulin Signaling GO:0008286 ↓ DECREASED

Downstream

Hyperandrogenism Obesity-related hyperinsulinemia increases ovarian androgen synthesis and lowers SHBG, raising bioactive androgen exposure.

Chronic Low-Grade Inflammation Visceral adiposity and insulin resistance contribute to the inflammatory state shared by PCOS, obesity, type 2 diabetes, and cardiovascular disease.

Show evidence (3 references)

PMID:12080440 SUPPORT Other

"Obesity, particularly the abdominal phenotype, may be partly responsible for insulin resistance and associated hyperinsulinemia in women with PCOS."

Supports a distinct adiposity-amplified insulin resistance node for obese PCOS.

PMID:12080440 SUPPORT Other

"Therefore, obesity-related hyperinsulinemia may play a key role in favouring hyperandrogenism in these women."

Supports the adiposity-to-hyperinsulinemia-to-hyperandrogenism causal route.

PMID:37213054 SUPPORT Other

"This disease causes menstrual, metabolic, and biochemical abnormalities such as hyperandrogenism, oligo-anovulatory menstrual cycles, polycystic ovary, hyperleptinemia, insulin resistance (IR), and cardiometabolic disorders, often associated with overweight or obesity and visceral adiposity."

Recent review evidence supports separating visceral-adiposity-associated PCOS metabolic dysfunction from nonobese mechanisms.

Ovulatory Dysfunction

Disrupted folliculogenesis with arrest at small antral stage leads to anovulation. Multiple small follicles accumulate (polycystic morphology) without dominant follicle selection.

Ovulation GO:0030728

Show evidence (3 references)

PMID:14671196 SUPPORT Human Clinical

"Because PCOS is associated with a 2- to 3-fold increase in growing FN, we investigated whether an increased AMH serum level correlates to other hormonal and/or U/S features of PCOS."

Documents the 2-3 fold increase in small growing follicle number characteristic of PCOS polycystic morphology.

PMID:14671196 SUPPORT Human Clinical

"Mean serum AMH level was markedly increased in the PCOS group (47.1 +/- 22.9 vs. 20.8 +/- 11.6 pmol/liter in controls; P < 0.0001), an increase in the same order of magnitude as the one of the FN in the 2- to 5-mm range at U/S (12.8 +/- 8.3 vs. 4.8 +/- 1.9; P < 0.0001, respectively)."

Shows parallel elevation of AMH levels and small antral follicle count in PCOS, implicating AMH in follicular arrest.

PMID:14671196 SUPPORT Human Clinical

"We hypothesize that an increased AMH tone within the cohort could be involved in the follicular arrest of PCOS, by interacting negatively with FSH at the time of selection."

Proposes mechanism by which elevated AMH interferes with FSH action to prevent dominant follicle selection in PCOS.

Oxidative and Endoplasmic Reticulum Stress

Synergistic oxidative stress (OS) and endoplasmic reticulum stress (ERS) form an intracellular stress hub that initiates autophagy-ferroptosis crosstalk in ovarian granulosa cells, driving follicular atresia and ovulatory dysfunction.

granulosa cell CL:0000501

Oxidative Stress Response GO:0006979 ↑ INCREASED Endoplasmic Reticulum Stress Response GO:0034976 ↑ INCREASED

Downstream

Autophagy-Ferroptosis Crosstalk in Granulosa Cell Death Oxidative and ER stress serve as the initiating hub that triggers downstream autophagy-ferroptosis crosstalk in granulosa cells.

Show evidence (1 reference)

PMID:42178591 SUPPORT Other

"the intracellular stress hub formed by the synergistic action of oxidative stress (OS) and endoplasmic reticulum stress (ERS) serves as the initiating factor"

Establishes OS and ERS synergy as the initiating hub driving granulosa cell dysfunction and autophagy-ferroptosis crosstalk in PCOS.

Autophagy-Ferroptosis Crosstalk in Granulosa Cell Death

Selective autophagy pathways (ferritinophagy and mitophagy) act as key amplifiers of ferroptosis-driven granulosa cell death, driving follicular atresia. The dynamic equilibrium between autophagy and ferroptosis is disrupted, leading to iron overload and energy collapse in granulosa cells.

granulosa cell CL:0000501

Autophagy GO:0006914 ↑ INCREASED Ferroptosis GO:0097707 ↑ INCREASED

Downstream

Ovulatory Dysfunction Ferroptosis-driven granulosa cell death leads to follicular atresia and failure of follicular maturation, resulting in ovulatory dysfunction.

Show evidence (2 references)

PMID:42178591 SUPPORT Other

"The dysfunction of GCs in PCOS is not an isolated event involving a single mode of cell death, but rather a pathological crosstalk arising from the disruption of the dynamic equilibrium between autophagy and ferroptosis."

Demonstrates that granulosa cell dysfunction in PCOS results from disrupted autophagy-ferroptosis balance rather than single death pathways.

PMID:42178591 SUPPORT Other

"selective autophagy (e.g., ferritinophagy and mitophagy) acts as a key amplifier of ferroptosis by exacerbating iron overload and energy collapse"

Identifies selective autophagy mechanisms as amplifiers of ferroptosis via iron and energy dysregulation.

Gut Microbiome Dysregulation and Gut-Ovarian Axis Inflammation

Dysbiosis-driven gut microbiome dysfunction amplifies low-grade chronic inflammation via the gut-ovarian axis, exacerbating granulosa cell dysfunction and follicular atresia through long-range immune and metabolic signaling.

Inflammatory Response GO:0006954 ↑ INCREASED

Downstream

Chronic Low-Grade Inflammation Gut microbiome dysregulation amplifies systemic low-grade chronic inflammation via the gut-ovarian axis.

Show evidence (1 reference)

PMID:42178591 SUPPORT Other

"the gut-ovarian axis's long-range amplification effect, mediated by gut microbiome (GM) dysregulation and low-grade chronic inflammation (LGI), collectively disrupting cellular homeostasis"

Establishes the gut-ovarian axis as a long-range amplification mechanism linking microbiome dysregulation to granulosa cell dysfunction via chronic inflammation.

Chronic Low-Grade Inflammation

Elevated inflammatory markers (CRP, IL-6) contribute to insulin resistance and cardiovascular risk in PCOS.

Inflammatory Response GO:0006954

Show evidence (2 references)

PMID:39036884 SUPPORT Human Clinical

"Polycystic ovarian syndrome (PCOS) is related to pro-apoptotic and pro-inflammatory conditions generated by Endoplasmic reticulum (ER) stress."

Establishes the link between ER stress, inflammation, and apoptotic pathways in PCOS pathophysiology.

PMID:39036884 SUPPORT Human Clinical

"The levels of TNF-α (p = 0.009), IL-18 (p = 0.003), IL-6 (p = 0.013) and active caspase-3 (p = 0.012) were also statistically significant lower in the therapy group."

Clinical trial evidence demonstrating elevated TNF-α, IL-18, and IL-6 levels in PCOS patients at baseline, confirming chronic inflammatory state.

Granulosa Cell Ferroptosis-Autophagy Crosstalk

Granulosa cell dysfunction in PCOS arises from pathological crosstalk between autophagy and ferroptosis. An intracellular stress hub formed by oxidative stress and endoplasmic reticulum stress initiates this cascade. Elevated PCSK9 induces lipid metabolism abnormalities that activate AMP-activated protein kinase (AMPK) and glycogen synthase kinase 3β (GSK-3β) signaling, triggering apoptosis as an upstream driver of granulosa cell death. Selective autophagy mechanisms (ferritinophagy and mitophagy) amplify ferroptosis through iron overload and energy collapse, driving follicular atresia and ovulatory dysfunction. This dysequilibrium is further amplified by gut-ovarian axis dysregulation, circadian rhythm disruption, and epigenetic reprogramming.

Granulosa cell CL:0000501

Ferroptosis GO:0097707 ↑ INCREASED Autophagy GO:0006914 ↑ INCREASED Response to Oxidative Stress GO:0006979 ↑ INCREASED Response to Endoplasmic Reticulum Stress GO:0034976 ↑ INCREASED Lipid Metabolic Process GO:0006629 ↑ INCREASED Signal Transduction GO:0007165 ↑ INCREASED Apoptotic Process GO:0006915 ↑ INCREASED

Downstream

Ovulatory Dysfunction Granulosa cell ferroptosis and autophagy-amplified cell death drive follicular atresia and prevent dominant follicle selection, resulting in anovulation.

Chronic Low-Grade Inflammation The intracellular stress hub and gut-ovarian axis dysregulation amplify chronic inflammatory signaling, perpetuating granulosa cell dysfunction.

Show evidence (6 references)

PMID:42178591 SUPPORT Other

"The dysfunction of GCs in PCOS is not an isolated event involving a single mode of cell death, but rather a pathological crosstalk arising from the disruption of the dynamic equilibrium between autophagy and ferroptosis."

Review establishes ferroptosis-autophagy crosstalk as central to granulosa cell dysfunction in PCOS, providing mechanistic framework for follicular atresia.

PMID:42178591 SUPPORT Other

"the intracellular stress hub formed by the synergistic action of oxidative stress (OS) and endoplasmic reticulum stress (ERS) serves as the initiating factor."

Identifies oxidative and ER stress as initiating factors driving the ferroptosis-autophagy dysfunction in granulosa cells.

PMID:42178591 SUPPORT Other

"selective autophagy (e.g., ferritinophagy and mitophagy) acts as a key amplifier of ferroptosis by exacerbating iron overload and energy collapse."

Demonstrates how selective autophagy pathways (ferritinophagy and mitophagy) amplify ferroptosis through iron dysregulation and cellular energy depletion.

+ 3 more references

Granulosa Cell Apoptosis via PCSK9-Lipid Dysregulation

Elevated PCSK9 (proprotein convertase subtilisin/kexin type-9) in ovarian follicles triggers lipid metabolism abnormalities that activate AMP-activated protein kinase (AMPK) and glycogen synthase kinase 3β (GSK-3β), leading to granulosa cell apoptosis. This PCSK9-lipid-AMPK/GSK-3β cascade represents a distinct apoptotic pathway in granulosa cell death, independent of the ferroptosis-autophagy crosstalk mechanism, and may contribute to follicular atresia and ovulatory dysfunction in PCOS.

Granulosa cell CL:0000501

Phosphorylation (AMPK and GSK-3β Activation) GO:0016310 ↑ INCREASED Apoptosis GO:0006915 ↑ INCREASED Lipid Metabolism Abnormalities GO:0006629 ⚠ ABNORMAL

Downstream

Ovulatory Dysfunction PCSK9-driven granulosa cell apoptosis leads to loss of granulosa cell support for follicular maturation, resulting in follicular arrest and anovulation.

Show evidence (2 references)

PMID:42093080 SUPPORT Model Organism

"elevated PCSK9 levels induce lipid metabolism abnormalities in PCOS mice, subsequently activating AMP-activated protein kinase and glycogen synthase kinase 3β within follicles. This activation triggers granulosa cell apoptosis"

Direct mechanistic evidence in PCOS model mice establishing the PCSK9 → lipid abnormality → AMPK/GSK-3β → apoptosis cascade as a driver of granulosa cell death.

PMID:42093080 SUPPORT Model Organism

"Granulosa cell apoptosis in the ovaries is one of the primary factors affecting follicular growth and development as well as oocyte maturation in PCOS, yet its pathological mechanisms remain unclear."

Establishes granulosa cell apoptosis as a primary mechanism impairing follicular development and oocyte maturation in PCOS, motivating mechanistic investigation of upstream drivers like PCSK9.

Population-Specific Metabolic vs. Inflammatory Dysregulation

PCOS manifests with distinct molecular pathophysiology across populations. East Asian PCOS exhibits predominant enrichment of metabolic dysregulation pathways with emphasis on insulin/IGF signaling and gonadotropin receptor pathways. European PCOS shows a stronger inflammatory and immune-related signature, featuring enrichment of the TLR4-NF-κB-NLRP3 signaling axis. This population-specific molecular heterogeneity suggests distinct pathophysiological drivers and therapeutic opportunities across ancestries.

INS hgnc:6081 INSR hgnc:6091 IGF1R hgnc:5465 FSHR hgnc:3969 LHCGR hgnc:6585 NFKB1 hgnc:7794 IRF1 hgnc:6116

Insulin Receptor Signaling GO:0008286 Inflammatory Response GO:0006954

Show evidence (3 references)

PMID:42365073 SUPPORT Computational

"Notably, our analyses reveal a predominant enrichment of metabolic dysregulation-associated pathways in East Asian PCOS, whereas European PCOS exhibits a stronger inflammatory and immune-related signature."

Population-stratified gene prioritization reveals distinct metabolic versus inflammatory molecular signatures across East Asian and European populations, supported by transcriptomic validation in PCOS patient samples.

PMID:42365073 SUPPORT Computational

"genes like INS, INSR and IGF1R implicating insulin signaling and FSHR, LHCGR involving gonadotropin related signaling were exclusively present in the EAS population"

East Asian PCOS prioritizes insulin/IGF and gonadotropin signaling genes, reflecting the metabolic and hormonal dysfunction-dominant phenotype in this population.

PMID:42365073 SUPPORT Computational

"immune-related genes were differentially prioritized in the EUR population (Supplementary Data 2, II) with, NF-B1, APP, IRF1 and few others"

European PCOS shows preferential prioritization of immune-centric genes, reflecting the stronger inflammatory and immune-related signature of this population.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

6

Genitourinary 2

Irregular Menstruation VERY_FREQUENT Irregular menstruation HP:0000858

Show evidence (1 reference)

PMID:14671196 SUPPORT Human Clinical

"We hypothesize that an increased AMH tone within the cohort could be involved in the follicular arrest of PCOS, by interacting negatively with FSH at the time of selection."

Follicular arrest due to elevated AMH directly leads to anovulation and irregular menstruation in PCOS.

Infertility FREQUENT Infertility HP:0000789

Show evidence (1 reference)

PMID:14671196 SUPPORT Human Clinical

"Because PCOS is associated with a 2- to 3-fold increase in growing FN, we investigated whether an increased AMH serum level correlates to other hormonal and/or U/S features of PCOS."

Anovulation from follicular arrest is the primary mechanism of infertility in PCOS, linked to elevated AMH and disrupted follicle maturation.

Immune 1

Acne FREQUENT Acne HP:0001061

Integument 2

Hirsutism VERY_FREQUENT Hirsutism HP:0001007

Show evidence (1 reference)

PMID:38152131 SUPPORT Other

"Compelling evidence suggests that hyperandrogenism is not just a primary feature of PCOS. Instead, it may be a causative factor for this condition."

Hyperandrogenism drives hirsutism and other androgen-mediated dermatological manifestations in PCOS.

Alopecia OCCASIONAL Alopecia HP:0001596

Androgenic pattern

Growth 1

Obesity FREQUENT Obesity HP:0001513

🧬

Genetic Associations

4

DENND1A (Risk Factor)

THADA (Risk Factor)

LHCGR (Risk Factor)

FSHR (Risk Factor)

💊

Medical Actions

9

Combined Oral Contraceptives

First-line for menstrual irregularity and hyperandrogenism.

Metformin

Improves insulin sensitivity and may restore ovulation.

Spironolactone

Anti-androgen for hirsutism and acne.

Letrozole

First-line ovulation induction for fertility.

Clomiphene Citrate

Alternative ovulation induction agent.

Lifestyle Modification

Weight loss improves all PCOS features.

ERBB Family Signaling Inhibitors

Action: Pharmacotherapy NCIT:C15986

ERBB3 and ERBB2 signaling are central nodes in both East Asian and European PCOS genetic networks. ERBB-family receptor tyrosine kinase inhibition is a computationally identified candidate population-agnostic target for disrupting tyrosine kinase signaling implicated in follicular dysfunction and inflammatory amplification. This is an in silico target prediction from gene prioritization and has not been clinically tested in PCOS; no specific inhibitor is nominated by the source.

Show evidence (1 reference)

PMID:42365073 SUPPORT Computational

"EGFR, ERBB3, and YAP1 present in the network of both the population , are involved in signaling by receptor tyrosine kinases and Hippo which are known for their role in PCOS"

Gene prioritization in both East Asian and European populations identifies ERBB family members as highly ranked druggable targets with direct therapeutic potential.

Growth Factor Receptor Inhibitors (FGFR, EGFR, PDGFRA)

Action: Pharmacotherapy NCIT:C15986

FGFR, EGFR, and PDGFRA signaling pathways are preferentially enriched in East Asian PCOS and are implicated in follicular growth and ovulation. Inhibition of these growth factor receptors is a computationally identified population-specific candidate target for metabolic-dominant PCOS phenotypes. This is an in silico target prediction from gene prioritization and has not been clinically tested in PCOS; no specific inhibitor is nominated by the source.

Show evidence (1 reference)

PMID:42365073 SUPPORT Computational

"signaling pathways involving EGFR, PDGFRA and FGFR which are exclusively enriched due to peripheral genes (Figure 2A (iv)) are within the top priority pathways in EAS population."

Exclusive prioritization of FGFR/EGFR/PDGFRA pathways in East Asian PCOS identifies these as population-specific therapeutic targets for metabolic-dysregulation-dominant disease.

NF-kB and Inflammasome Pathway Inhibitors

Action: Pharmacotherapy NCIT:C15986

European PCOS exhibits preferential enrichment of TLR4-NF-kB-NLRP3 signaling and inflammasome activation. NF-kB and NLRP3 inflammasome inhibition are computationally identified population-specific candidate targets for inflammatory-dominant PCOS phenotypes, addressing chronic low-grade inflammation driven by immune pathway dysregulation. This is an in silico target prediction from gene prioritization and has not been clinically tested in PCOS; no specific inhibitor is nominated by the source.

Show evidence (1 reference)

PMID:42365073 SUPPORT Computational

"the prioritization of the TLR4 -NF-κB-NLRP3 signaling axis in EUR population"

Gene prioritization in European PCOS reveals preferential dysregulation of TLR4-NF-kB-NLRP3 inflammatory axis, identifying NF-kB and inflammasome inhibition as population-specific therapeutic strategies for immune-dominant disease.

🌍

Environmental Factors

3

Obesity

Exacerbates insulin resistance and hyperandrogenism

Sedentary Lifestyle

Worsens metabolic features

Prenatal Androgen Exposure

May program PCOS phenotype

🔬

Biochemical Markers

5

Testosterone (Elevated)

Context: Total and free testosterone

Show evidence (1 reference)

PMID:14671196 SUPPORT Human Clinical

"AMH was also positively related to the serum testosterone and androstenedione levels, in PCOS exclusively (P < 0.0005 and <0.002, respectively)."

Documents positive correlation between AMH and testosterone levels in PCOS patients.

LH (Elevated)

Context: Often elevated LH:FSH ratio

Show evidence (1 reference)

PMID:24014605 SUPPORT Human Clinical

"A higher proportion of theca cells from anovulatory PCO expressed LHCGR protein when compared with control ovaries (P = 0.01)."

Increased LH receptor expression in PCOS theca cells supports elevated LH action in driving androgen production.

SHBG (Decreased)

Context: Increases free androgen index

Show evidence (1 reference)

PMID:40013621 SUPPORT Other

"Hyperinsulinemia (i.e., elevated insulin without hypoglycemia) is a common metabolic feature of PCOS that worsens its reproductive symptoms by exacerbating pituitary hormone imbalances and increasing levels of bioactive androgens."

Hyperinsulinemia suppresses hepatic SHBG production, increasing free bioactive androgens.

Fasting Insulin (Elevated)

Context: Insulin resistance

Show evidence (1 reference)

PMID:40013621 SUPPORT Other

"However, it is challenging to define the sequential relationship between insulin sensitivity and insulin secretion, as they are tightly interlinked, and evidence suggests that hyperinsulinemia can alternatively precede insulin resistance."

Hyperinsulinemia is a core feature in PCOS that may precede or result from insulin resistance.

Anti-Mullerian Hormone (Elevated)

Context: Reflects increased antral follicle count

Show evidence (1 reference)

PMID:14671196 SUPPORT Human Clinical

"Mean serum AMH level was markedly increased in the PCOS group (47.1 +/- 22.9 vs. 20.8 +/- 11.6 pmol/liter in controls; P < 0.0001), an increase in the same order of magnitude as the one of the FN in the 2- to 5-mm range at U/S (12.8 +/- 8.3 vs. 4.8 +/- 1.9; P < 0.0001, respectively)."

Demonstrates markedly elevated AMH levels in PCOS patients paralleling increased small antral follicle count.

{ }

Source YAML

click to show

name: Polycystic Ovary Syndrome
creation_date: '2025-12-18T17:01:35Z'
updated_date: '2026-02-17T21:53:14Z'
description: >-
  Polycystic ovary syndrome is a common endocrine and reproductive disorder of
  women of reproductive age, defined by the combination of hyperandrogenism,
  ovulatory dysfunction, and polycystic ovarian morphology. Its pathophysiology
  centers on hypothalamic-pituitary dysregulation with increased LH-driven
  ovarian androgen production and on insulin resistance that amplifies androgen
  excess, although lean and obese subtypes differ in the relative contribution
  of intrinsic versus adiposity-amplified insulin signaling defects. Clinical
  features include irregular menstruation, hirsutism, acne, and infertility,
  with downstream metabolic consequences and chronic low-grade inflammation.
category: Complex
parents:
- Endocrine Disease
- Reproductive Disease
disease_term:
  preferred_term: polycystic ovary syndrome
  term:
    id: MONDO:0008487
    label: polycystic ovary syndrome
has_subtypes:
- name: Lean PCOS
  display_name: Lean / nonobese PCOS
  classification: adiposity_stratum
  description: >
    PCOS occurring without obesity. This stratum is useful for separating
    intrinsic, obesity-independent insulin signaling defects and
    neuroendocrine/ovarian androgen mechanisms from adiposity-amplified
    metabolic dysfunction. Lean PCOS is still heterogeneous; some lean affected
    groups may have normal insulin sensitivity.
  evidence:
  - reference: PMID:1397698
    reference_title: Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These defects in insulin action appear to represent intrinsic abnormalities that are independent of obesity, metabolic derangements, body fat topography, and sex hormone levels."
    explanation: >
      Euglycemic clamp and adipocyte data support an obesity-independent
      intrinsic insulin-action defect relevant to nonobese PCOS.
  - reference: PMID:23065822
    reference_title: "Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications."
    supports: PARTIAL
    evidence_source: OTHER
    snippet: "There is general agreement that obese women with PCOS are insulin resistant, but some groups of lean affected women may have normal insulin sensitivity."
    explanation: >
      The review supports subtype heterogeneity within lean PCOS, so lean status
      should not be modeled as synonymous with insulin resistance.
- name: Obese PCOS
  display_name: Obese / adiposity-amplified PCOS
  classification: adiposity_stratum
  description: >
    PCOS with overweight, obesity, or abdominal/visceral adiposity. This stratum
    emphasizes adiposity-driven insulin resistance, hyperinsulinemia, lower SHBG,
    and inflammatory amplification of androgen excess and anovulation.
  evidence:
  - reference: PMID:12080440
    reference_title: Obesity and the polycystic ovary syndrome.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Obesity, particularly the abdominal phenotype, may be partly responsible for insulin resistance and associated hyperinsulinemia in women with PCOS."
    explanation: >
      Review evidence supports abdominal obesity as an amplifier of insulin
      resistance and hyperinsulinemia in PCOS.
  - reference: PMID:12080440
    reference_title: Obesity and the polycystic ovary syndrome.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Irrespective of the pathogenetic mechanism involved, obese PCOS women have more severe hyperandrogenism and related clinical features (such as hirsutism, menstrual abnormalities and anovulation) than normal-weight PCOS women."
    explanation: >
      The subtype description is supported by evidence that obesity worsens
      androgenic and reproductive PCOS features.
mechanistic_hypotheses:
- hypothesis_group_id: androgen_first_feedback_model
  hypothesis_label: Androgen-First Feedback Model
  status: ALTERNATIVE
  applies_to_subtypes:
  - Lean PCOS
  - Obese PCOS
  description: >
    Intrinsic ovarian/adrenal androgen excess, potentially reinforced by
    heightened LH action and theca-cell steroidogenic machinery, is the initiating
    lesion. Androgen excess then promotes insulin resistance and hyperinsulinemia,
    disrupts hypothalamic steroid feedback, and contributes to visceral adiposity,
    closing an androgen-insulin-adiposity feedback loop.
  evidence:
  - reference: PMID:38152131
    reference_title: "Androgen excess: a hallmark of polycystic ovary syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Compelling evidence suggests that hyperandrogenism is not just a primary feature of PCOS. Instead, it may be a causative factor for this condition."
    explanation: >
      This review explicitly frames androgen excess as a possible causal driver,
      supporting the androgen-first hypothesis group.
  - reference: PMID:35356614
    reference_title: "Association of Insulin Resistance and Elevated Androgen Levels with Polycystic Ovarian Syndrome (PCOS): A Review of Literature."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "However, the overexposure of androgen has direct and specific influence on the development of insulin resistance."
    explanation: >
      Supports the androgen-to-insulin-resistance arm of the proposed feedback
      model.
- hypothesis_group_id: insulin_hyperinsulinemia_first_model
  hypothesis_label: Insulin/Hyperinsulinemia-First Model
  status: ALTERNATIVE
  applies_to_subtypes:
  - Lean PCOS
  - Obese PCOS
  description: >
    Primary insulin resistance or primary hyperinsulinemia initiates the
    endocrine-metabolic loop. High insulin acts as a co-gonadotropin in the ovary
    and lowers hepatic SHBG, increasing bioactive androgen exposure; the resulting
    hyperandrogenism can then worsen insulin resistance and adiposity.
  evidence:
  - reference: PMID:40013621
    reference_title: "Reappraising the relationship between hyperinsulinemia and insulin resistance in PCOS."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Hyperinsulinemia (i.e., elevated insulin without hypoglycemia) is a common metabolic feature of PCOS that worsens its reproductive symptoms by exacerbating pituitary hormone imbalances and increasing levels of bioactive androgens."
    explanation: >
      Supports hyperinsulinemia as an upstream amplifier of pituitary imbalance
      and bioactive androgen excess.
  - reference: PMID:23065822
    reference_title: "Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Insulin functions as a co-gonadotropin through its cognate receptor to modulate ovarian steroidogenesis."
    explanation: >
      Supports the ovarian steroidogenesis route by which hyperinsulinemia can
      increase androgen production.
- hypothesis_group_id: neuroendocrine_lh_first_model
  hypothesis_label: Neuroendocrine LH-Pulse Model
  status: ALTERNATIVE
  applies_to_subtypes:
  - Lean PCOS
  - Obese PCOS
  description: >
    Impaired hypothalamic-pituitary sensitivity to ovarian steroid negative
    feedback maintains rapid LH/GnRH pulse secretion. Elevated LH signaling then
    drives theca-cell androgen biosynthesis, while androgen excess further
    impairs steroid feedback and can secondarily worsen insulin resistance.
  evidence:
  - reference: PMID:11095431
    reference_title: "Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The majority of patients have elevated LH levels in plasma and a persistent rapid frequency of LH (GnRH) pulse secretion, the mechanisms of which are unclear."
    explanation: >
      Supports the upstream neuroendocrine abnormality represented by this
      hypothesis group.
  - reference: PMID:11095431
    reference_title: "Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These results suggest that although the elevated LH pulse frequency in PCOS may in part reflect impaired sensitivity to E2 and P, continuing actions of hyperandrogenemia are important for sustaining the abnormal hypothalamic sensitivity to feedback inhibition by ovarian steroids."
    explanation: >
      Supports the feedback component connecting androgen excess and persistent
      hypothalamic-pituitary dysregulation.
- hypothesis_group_id: population_stratified_mechanistic_heterogeneity
  hypothesis_label: Population-Stratified Mechanistic Heterogeneity
  status: EMERGING
  description: >
    PCOS pathophysiology exhibits significant population-specific molecular
    phenotypes. East Asian populations show a predominant enrichment of metabolic
    dysregulation-associated pathways (insulin receptor signaling, GLUT4
    translocation, metabolic syndrome), whereas European populations exhibit a
    stronger inflammatory and immune-related signature (NF-kB signaling, innate
    immunity, and interleukin/cytokine and inflammasome pathways). These
    population-specific mechanistic differences may drive differential therapeutic
    responsiveness and clinical phenotypes across ancestry groups.
  evidence:
  - reference: PMID:42365073
    reference_title: "Gene prioritization across ancestries uncovers distinct molecular pathophysiology and therapeutic landscape in polycystic ovary syndrome."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: "our analyses reveal a predominant enrichment of metabolic dysregulation-associated pathways in East Asian PCOS, whereas European PCOS exhibits a stronger inflammatory and immune-related signature"
    explanation: >
      Population-aware gene prioritization framework combining regulatory genomics,
      QTLs, and protein networks reveals distinct pathway enrichment patterns:
      East Asian PCOS driven by metabolic dysfunction, European PCOS by
      inflammation/immunity, with implications for subtype-specific therapeutics.
  - reference: PMID:42365073
    reference_title: "Gene prioritization across ancestries uncovers distinct molecular pathophysiology and therapeutic landscape in polycystic ovary syndrome."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: "These population-specific molecular phenotypes were further supported by transcriptomic data from PCOS patient samples"
    explanation: >
      Patient transcriptome data validate population-stratified pathway enrichment,
      confirming mechanistic divergence between East Asian and European PCOS
      cohorts rather than technical artifacts.
discussions:
- discussion_id: gap_pcos_causal_hierarchy_by_adiposity
  prompt: >
    In which PCOS patient strata is androgen excess, insulin resistance or
    hyperinsulinemia, adiposity, or hypothalamic-pituitary dysregulation the
    initiating event rather than an amplifier of an already established
    endocrine-metabolic cycle?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Hyperandrogenism
  - pathophysiology#Intrinsic Post-Receptor Insulin Signaling Defect
  - pathophysiology#Adiposity-Amplified Insulin Resistance
  - pathophysiology#Hypothalamic-Pituitary Dysregulation
  rationale: >
    Current evidence supports bidirectional reinforcement among androgen excess,
    hyperinsulinemia/insulin resistance, and adiposity, but it does not establish
    a single causal sequence that applies across lean and obese PCOS. The entry
    therefore models three competing or superimposed hypothesis groups and
    annotates causal edges by subgroup.
  evidence:
  - reference: PMID:38637590
    reference_title: Polycystic ovary syndrome.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Treatment remains ad hoc owing to limited understanding of underlying mechanisms, highlighting the need for research delineating the aetiology and pathophysiology of the syndrome."
    explanation: >
      The Disease Primer frames unresolved PCOS mechanisms as a research need,
      supporting the explicit knowledge-gap discussion.
  - reference: PMID:40013621
    reference_title: "Reappraising the relationship between hyperinsulinemia and insulin resistance in PCOS."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Considering the heterogeneous nature of PCOS, it is improbable that its metabolic characteristics always follow the same progression."
    explanation: >
      Supports subtype-specific causal hierarchy rather than a single universal
      insulin-resistance sequence.
- discussion_id: gap_pcos_granulosa_apoptosis_pcsk9
  prompt: >-
    Granulosa cell apoptosis is a primary driver of follicular arrest and
    impaired oocyte maturation in PCOS, but the upstream triggers of that
    apoptosis remain unclear. Is a PCSK9 -> lipid metabolism abnormality ->
    AMPK/GSK-3beta -> apoptosis cascade a primary, translatable mechanism in
    human PCOS, and how does it relate to the parallel ferroptosis-autophagy
    and ER/oxidative-stress death programs already described in granulosa cells?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Granulosa Cell Ferroptosis-Autophagy Crosstalk
  - pathophysiology#Ovulatory Dysfunction
  - pathophysiology#Chronic Low-Grade Inflammation
  rationale: >-
    Granulosa cell death is recognized as one of the primary factors impairing
    follicular growth, development, and oocyte maturation in PCOS, yet its
    upstream pathological triggers have been poorly defined. Teng et al. (2026)
    propose a specific cascade in which elevated proprotein convertase
    subtilisin/kexin type-9 (PCSK9) drives lipid metabolism abnormalities that
    activate AMP-activated protein kinase (AMPK) and glycogen synthase kinase
    3beta (GSK-3beta) within follicles, triggering granulosa cell apoptosis and
    impairing ovarian function. Several questions remain unresolved. First, the
    cascade was established in PCOS model mice and primary follicles, so whether
    elevated PCSK9 is a primary driver in human PCOS rather than a species- or
    model-specific finding is unknown. Second, the proximal mechanism by which
    PCSK9-driven lipid abnormalities impair granulosa cell survival
    (intracellular lipid-droplet accumulation versus altered membrane lipid
    composition versus lipotoxic oxidative stress) is undefined. Third, it is
    unclear whether AMPK/GSK-3beta is the dominant death pathway or whether it
    operates in parallel with the previously modeled ferroptosis-autophagy
    crosstalk and ER/oxidative-stress programs that also drive granulosa cell
    loss. Resolving the relative contribution and translatability of these
    death pathways would clarify whether PCSK9 inhibition is a viable
    PCOS-directed therapeutic target.
  proposed_experiments:
  - experiment_id: exp_pcos_pcsk9_granulosa_apoptosis_human_vs_model
    name: PCSK9-lipid-AMPK/GSK-3beta apoptosis cascade in human granulosa cells with model comparison
    description: >-
      Compare PCSK9 expression, follicular-fluid and intracellular lipid
      profiles, AMPK/GSK-3beta activation status, and apoptosis markers in
      granulosa cells from PCOS patients versus controls, alongside PCSK9
      gain- and loss-of-function in primary granulosa cells and PCOS model
      mice. Use pharmacologic PCSK9 inhibition and AMPK/GSK-3beta blockade to
      test whether interrupting the cascade rescues granulosa cell survival and
      follicular development, and assay ferroptosis/autophagy and ER-stress
      markers in parallel to determine pathway dominance versus redundancy.
    experiment_type:
      preferred_term: mechanistic intervention study with human-tissue and animal-model arms
    readouts:
    - name: Granulosa cell apoptosis after PCSK9 modulation
      target: pathophysiology#Granulosa Cell Ferroptosis-Autophagy Crosstalk
      description: >-
        Quantify granulosa cell apoptosis (caspase-3 activity, TUNEL, annexin V)
        in response to PCSK9 overexpression, PCSK9 inhibition, and AMPK/GSK-3beta
        blockade in human and mouse granulosa cells.
      assays:
      - preferred_term: TUNEL apoptosis assay
      - preferred_term: caspase-3 activity assay
      direction: POSITIVE
    - name: Lipid handling and AMPK/GSK-3beta signaling
      target: pathophysiology#Granulosa Cell Ferroptosis-Autophagy Crosstalk
      description: >-
        Measure intracellular lipid-droplet content, membrane lipid composition,
        and phosphorylation of AMPK and GSK-3beta to map the proximal
        lipotoxic-to-apoptotic signaling link.
      assays:
      - preferred_term: intracellular lipid quantification
      - preferred_term: phospho-protein immunoblotting
      direction: POSITIVE
    - name: Follicular development and ovulatory rescue
      target: pathophysiology#Ovulatory Dysfunction
      description: >-
        Assess antral follicle counts, dominant follicle selection, ovulation
        rate, and oocyte maturation after cascade interruption in PCOS model
        mice to test functional reversibility.
      assays:
      - preferred_term: ovarian histomorphometry
      - preferred_term: oocyte maturation scoring
      direction: NEGATIVE
    decision_criterion: >-
      The PCSK9-lipid-AMPK/GSK-3beta cascade is supported as a primary,
      translatable apoptosis driver if elevated PCSK9 and AMPK/GSK-3beta
      activation are reproducibly associated with increased granulosa cell
      apoptosis in human PCOS tissue, PCSK9 or AMPK/GSK-3beta inhibition
      reduces apoptosis and restores follicular development in models, and the
      effect is at least partially independent of the ferroptosis-autophagy and
      ER-stress death programs.
    would_support:
    - pathophysiology#Granulosa Cell Ferroptosis-Autophagy Crosstalk
    - pathophysiology#Ovulatory Dysfunction
  evidence:
  - reference: PMID:42093080
    reference_title: "Lipid metabolism abnormalities induced by elevated PCSK9 in polycystic ovary syndrome mice lead to ovarian granulosa cell apoptosis via AMPK and GSK-3β."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "The mechanism underlying granulosa cell apoptosis in polycystic ovary syndrome remains unclear."
    explanation: >-
      Directly states the unresolved mechanism that this knowledge-gap
      discussion captures.
  - reference: PMID:42093080
    reference_title: "Lipid metabolism abnormalities induced by elevated PCSK9 in polycystic ovary syndrome mice lead to ovarian granulosa cell apoptosis via AMPK and GSK-3β."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Results demonstrated that elevated PCSK9 levels induce lipid metabolism abnormalities in PCOS mice, subsequently activating AMP-activated protein kinase and glycogen synthase kinase 3β within follicles."
    explanation: >-
      Establishes the proposed PCSK9 -> lipid abnormality -> AMPK/GSK-3beta
      cascade in PCOS model mice that the gap and proposed experiments
      interrogate for human translatability.
- discussion_id: gap_pcos_population_specific_therapeutics
  prompt: >-
    Given the distinct population-stratified molecular phenotypes of PCOS
    (metabolic-dominant in East Asian populations, inflammatory-dominant in
    European populations), are currently approved therapies (metformin, oral
    contraceptives, spironolactone) equally effective across ancestry groups?
    Should therapeutic prioritization differ by population-specific mechanism,
    with metabolic pathway inhibitors favored in East Asian PCOS and
    immunomodulatory or anti-inflammatory agents in European PCOS?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Intrinsic Post-Receptor Insulin Signaling Defect
  - pathophysiology#Adiposity-Amplified Insulin Resistance
  - pathophysiology#Chronic Low-Grade Inflammation
  rationale: >-
    Population-stratified mechanistic analyses reveal that East Asian PCOS is
    enriched for metabolic dysregulation pathways while European PCOS exhibits
    stronger inflammatory and immune signatures. The heterogeneous molecular
    architecture suggests that therapeutic responses may vary by ancestry,
    yet current PCOS treatment guidelines do not account for mechanistic
    diversity. Whether therapies targeting the predominant mechanism in each
    population (e.g., metabolic pathway inhibitors for East Asian PCOS,
    anti-inflammatory agents for European PCOS) would improve clinical outcomes
    relative to universal treatment remains untested.
  evidence:
  - reference: PMID:42365073
    reference_title: "Gene prioritization across ancestries uncovers distinct molecular pathophysiology and therapeutic landscape in polycystic ovary syndrome."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: "integration of genetic evidence with a network-based approach enabled the identification of druggable targets lacking direct genetic cues"
    explanation: >
      Network-based gene prioritization strategy identifies population-specific
      druggable targets and therapeutic candidates that would not emerge from
      genetic associations alone, laying a foundation for ancestry-informed
      precision therapeutics.
- discussion_id: gap_pcos_pcsk9_granulosa_mouse_model_mismatch
  prompt: >-
    The PCSK9 -> lipid metabolism abnormality -> AMPK/GSK-3beta -> granulosa
    cell apoptosis cascade was established in PCOS model mice and primary mouse
    follicles. Is elevated PCSK9 a primary driver of granulosa cell apoptosis
    in human PCOS, or is its causal, apoptosis-initiating role a species- or
    model-specific finding that does not translate to human follicular biology?
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  attaches_to:
  - pathophysiology#Granulosa Cell Ferroptosis-Autophagy Crosstalk
  - pathophysiology#Ovulatory Dysfunction
  rationale: >-
    Granulosa cell apoptosis is recognized as a primary factor impairing
    follicular growth, oocyte maturation, and fertility in PCOS, but its
    upstream triggers remain unclear. Teng et al. (2026) provide mechanistic
    evidence in PCOS model mice that elevated proprotein convertase subtilisin/
    kexin type-9 (PCSK9) induces lipid metabolism abnormalities that activate
    AMP-activated protein kinase (AMPK) and glycogen synthase kinase 3beta
    (GSK-3beta) within follicles, triggering granulosa cell apoptosis. This is
    not a generic knowledge gap in which evidence is absent; rather, positive
    mechanistic evidence exists in a mouse model and the open question is its
    translational validity to human disease. The mismatch is mechanistically
    meaningful because PCSK9, hepatic and ovarian lipid handling, and
    androgen-driven lipotoxicity differ substantially between rodents and
    humans, so a cascade that is causal and apoptosis-initiating in mouse
    follicles could be absent, secondary, or merely correlative in human PCOS
    ovaries. Resolving whether elevated PCSK9 is a primary human driver is a
    prerequisite for treating PCSK9 inhibition as a PCOS-directed therapeutic
    target rather than a mouse-specific observation.
  proposed_experiments:
  - experiment_id: exp_pcos_pcsk9_human_granulosa_apoptosis
    name: PCSK9 and granulosa cell apoptosis in human PCOS follicles
    description: >-
      Measure PCSK9 levels in follicular fluid and granulosa cells from PCOS
      patients versus matched controls undergoing assisted reproduction, and
      correlate with intrafollicular lipid profiles, AMPK and GSK-3beta
      phosphorylation status, and granulosa cell apoptosis markers. Elevated
      PCSK9 reproducibly tracking with AMPK/GSK-3beta activation and increased
      apoptosis in human PCOS tissue would support translational validity of
      the mouse-derived cascade; absence of this association would indicate a
      model-specific finding.
    experiment_type:
      preferred_term: human granulosa cell apoptosis and follicular-fluid PCSK9 profiling study
    model_systems:
    - name: Human PCOS patient-derived granulosa cells
      description: >-
        Granulosa cells and matched follicular fluid recovered at oocyte
        retrieval from PCOS patients and ovulatory controls, preserving human
        ovarian lipid-handling and apoptosis biology.
      experimental_model_type: PRIMARY_CELL_CULTURE
  - experiment_id: exp_pcos_pcsk9_human_granulosa_perturbation
    name: PCSK9 gain- and loss-of-function in human granulosa cell apoptosis assay
    description: >-
      In primary human granulosa cells, test whether PCSK9 overexpression
      induces, and PCSK9 inhibition or AMPK/GSK-3beta blockade rescues,
      lipid accumulation and apoptosis. Demonstrating that PCSK9 manipulation
      causally raises and lowers human granulosa cell apoptosis through the
      AMPK/GSK-3beta axis would establish the cascade as a primary, translatable
      human mechanism rather than a mouse-restricted one.
    experiment_type:
      preferred_term: human granulosa cell apoptosis assay
    model_systems:
    - name: Primary human granulosa cell culture
      description: >-
        Cultured primary granulosa cells from human ovarian follicles used for
        PCSK9 gain- and loss-of-function manipulation and apoptosis readouts.
      experimental_model_type: PRIMARY_CELL_CULTURE
  notes: "Seeded from PMID:42093080 — Lipid metabolism abnormalities induced by elevated PCSK9 in polycystic ovary syndrome mice lead to ovarian granulosa cell apoptosis via AMPK and GSK-3β. Complements the same-source KNOWLEDGE_GAP discussion gap_pcos_granulosa_apoptosis_pcsk9; this entry adds the HUMAN_MODEL_MISMATCH translational framing and proposed human experiments."
pathophysiology:
- name: Hyperandrogenism
  description: >
    Excess androgen production from ovarian theca cells and adrenal glands
    leads to hirsutism, acne, and alopecia. Elevated LH stimulates theca
    cell androgen production.
  biological_processes:
  - preferred_term: Androgen Biosynthesis
    term:
      id: GO:0006702
      label: androgen biosynthetic process
  evidence:
  - reference: PMID:38152131
    reference_title: "Androgen excess: a hallmark of polycystic ovary syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Compelling evidence suggests that hyperandrogenism is not just a primary feature of PCOS. Instead, it may be a causative factor for this condition."
    explanation: This review establishes hyperandrogenism as potentially causative rather than merely symptomatic in PCOS pathophysiology.
  - reference: PMID:24014605
    reference_title: "Increased protein expression of LHCG receptor and 17α-hydroxylase/17-20-lyase in human polycystic ovaries."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "LHCGR and 17α-hydroxylase/17-20-lyase (CYP17A1) protein levels are increased in polycystic ovaries (PCOs)."
    explanation: Direct evidence of increased androgen biosynthetic machinery (CYP17A1) in PCOS ovaries, supporting intrinsic theca cell abnormality.
  - reference: PMID:24014605
    reference_title: "Increased protein expression of LHCG receptor and 17α-hydroxylase/17-20-lyase in human polycystic ovaries."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A significant increase in the intensity of immunostaining for CYP17A1 was identified in antral follicles in sections of PCO compared with ovaries from normal women (P = 0.04)."
    explanation: Quantitative demonstration of elevated CYP17A1 protein in polycystic ovaries compared to controls.
  - reference: PMID:24014605
    reference_title: "Increased protein expression of LHCG receptor and 17α-hydroxylase/17-20-lyase in human polycystic ovaries."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A higher proportion of theca cells from anovulatory PCO expressed LHCGR protein when compared with control ovaries (P = 0.01)."
    explanation: Increased LH receptor expression in theca cells explains heightened LH-driven androgen production in PCOS.
  downstream:
  - target: Intrinsic Post-Receptor Insulin Signaling Defect
    description: >
      Androgen excess can worsen insulin resistance and hyperinsulinemia,
      creating a self-perpetuating endocrine-metabolic loop.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - androgen receptor effects in skeletal muscle and adipose tissue
    - compensatory or androgen-augmented hyperinsulinemia
    hypothesis_groups:
    - androgen_first_feedback_model
  - target: Adiposity-Amplified Insulin Resistance
    description: >
      Hyperandrogenism favors visceral adiposity and adverse adipose signaling,
      which can amplify insulin resistance in obese PCOS.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - visceral fat deposition
    - adipokine and free-fatty-acid changes
    hypothesis_groups:
    - androgen_first_feedback_model
  - target: Hypothalamic-Pituitary Dysregulation
    description: >
      Ongoing androgen excess helps sustain abnormal hypothalamic sensitivity to
      estradiol/progesterone negative feedback, maintaining rapid LH/GnRH pulse
      secretion.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - impaired ovarian steroid negative feedback
    hypothesis_groups:
    - androgen_first_feedback_model
    - neuroendocrine_lh_first_model
  - target: Ovulatory Dysfunction
    description: >
      Elevated androgen exposure disrupts follicle maturation and contributes to
      anovulation.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - follicular arrest
    - impaired dominant follicle selection
    hypothesis_groups:
    - androgen_first_feedback_model
    - neuroendocrine_lh_first_model
- name: Hypothalamic-Pituitary Dysregulation
  description: >
    Impaired hypothalamic-pituitary sensitivity to estradiol and progesterone
    negative feedback maintains rapid LH/GnRH pulse secretion. Elevated LH then
    stimulates theca-cell androgen biosynthesis, while hyperandrogenism can
    sustain the abnormal feedback state.
  biological_processes:
  - preferred_term: Increased Luteinizing Hormone Secretion
    term:
      id: GO:0032275
      label: luteinizing hormone secretion
    modifier: INCREASED
  evidence:
  - reference: PMID:11095431
    reference_title: "Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The majority of patients have elevated LH levels in plasma and a persistent rapid frequency of LH (GnRH) pulse secretion, the mechanisms of which are unclear."
    explanation: >
      Human endocrine profiling supports elevated LH and rapid LH/GnRH pulse
      secretion as a PCOS pathophysiology node.
  - reference: PMID:11095431
    reference_title: "Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These results suggest that although the elevated LH pulse frequency in PCOS may in part reflect impaired sensitivity to E2 and P, continuing actions of hyperandrogenemia are important for sustaining the abnormal hypothalamic sensitivity to feedback inhibition by ovarian steroids."
    explanation: >
      Antiandrogen intervention restoring feedback sensitivity supports a
      bidirectional link between hyperandrogenism and hypothalamic-pituitary
      dysregulation.
  downstream:
  - target: Hyperandrogenism
    description: >
      Rapid LH/GnRH pulse secretion increases LH action on ovarian theca cells,
      promoting androgen biosynthesis.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - increased LH action at theca-cell LHCGR
    - CYP17A1-mediated androgen biosynthesis
    hypothesis_groups:
    - neuroendocrine_lh_first_model
- name: Intrinsic Post-Receptor Insulin Signaling Defect
  subtypes:
  - Lean PCOS
  description: >
    PCOS-associated insulin resistance can reflect an intrinsic post-binding or
    post-receptor defect in insulin signaling that is independent of obesity.
    Defective insulin receptor or IRS-associated signaling decreases metabolic
    glucose disposal while ovarian steroidogenic actions of insulin may remain
    active, allowing insulin and LH to amplify androgen production.
  biological_processes:
  - preferred_term: Insulin Signaling
    term:
      id: GO:0008286
      label: insulin receptor signaling pathway
    modifier: DECREASED
  evidence:
  - reference: PMID:1397698
    reference_title: Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Because insulin binding was not changed, we conclude that the major lesion causing insulin resistance in PCO is a striking decrease in insulin sensitivity secondary to a defect in the insulin receptor and/or postreceptor signal transduction."
    explanation: >
      Human clamp and adipocyte data support a post-binding/post-receptor insulin
      signaling defect as an intrinsic PCOS mechanism.
  - reference: PMID:11440917
    reference_title: Defects in insulin receptor signaling in vivo in the polycystic ovary syndrome (PCOS).
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We conclude that there is a physiologically relevant defect in insulin receptor signaling in PCOS that is independent of obesity and type 2 diabetes mellitus."
    explanation: >
      Skeletal muscle signaling data support an obesity-independent insulin
      receptor signaling defect in PCOS.
  - reference: PMID:23065822
    reference_title: "Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "There is a post-binding defect in receptor signaling likely due to increased receptor and insulin receptor substrate-1 serine phosphorylation that selectively affects metabolic but not mitogenic pathways in classic insulin target tissues and in the ovary."
    explanation: >
      Review evidence supports selective metabolic insulin resistance with
      preserved non-metabolic insulin signaling branches.
  - reference: PMID:40013621
    reference_title: "Reappraising the relationship between hyperinsulinemia and insulin resistance in PCOS."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Hyperinsulinemia (i.e., elevated insulin without hypoglycemia) is a common metabolic feature of PCOS that worsens its reproductive symptoms by exacerbating pituitary hormone imbalances and increasing levels of bioactive androgens."
    explanation: Demonstrates the direct mechanistic link between hyperinsulinemia and worsening of reproductive and androgenic features in PCOS.
  - reference: PMID:40013621
    reference_title: "Reappraising the relationship between hyperinsulinemia and insulin resistance in PCOS."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "However, it is challenging to define the sequential relationship between insulin sensitivity and insulin secretion, as they are tightly interlinked, and evidence suggests that hyperinsulinemia can alternatively precede insulin resistance."
    explanation: Challenges traditional causality and suggests hyperinsulinemia may be primary rather than compensatory in some PCOS cases.
  - reference: PMID:40013621
    reference_title: "Reappraising the relationship between hyperinsulinemia and insulin resistance in PCOS."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Notably, other drivers of hyperinsulinemia (outside of insulin resistance) may be highly relevant in the context of PCOS. For instance, high androgen levels can augment both hyperinsulinemia and insulin resistance, generating a self-perpetuating cycle of reproductive and metabolic dysfunction."
    explanation: Describes the vicious cycle where androgens exacerbate both hyperinsulinemia and insulin resistance in PCOS.
  downstream:
  - target: Hyperandrogenism
    description: >
      Hyperinsulinemia arising from impaired insulin signaling can act as a
      co-gonadotropin and increase bioactive androgen exposure.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - compensatory hyperinsulinemia
    - ovarian insulin receptor signaling
    - hepatic SHBG suppression
    hypothesis_groups:
    - insulin_hyperinsulinemia_first_model
  - target: Ovulatory Dysfunction
    description: >
      Hyperinsulinemia and androgen amplification contribute to follicular arrest
      and anovulation.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - increased bioactive androgens
    - altered pituitary hormone balance
    hypothesis_groups:
    - insulin_hyperinsulinemia_first_model
- name: Adiposity-Amplified Insulin Resistance
  subtypes:
  - Obese PCOS
  description: >
    Abdominal or visceral adiposity amplifies insulin resistance and
    hyperinsulinemia in susceptible PCOS patients. This pathway separates
    obesity-related hepatic/adipose insulin resistance from intrinsic lean-PCOS
    insulin signaling defects and explains why obesity worsens androgenic and
    reproductive features without being required for PCOS.
  biological_processes:
  - preferred_term: Insulin Signaling
    term:
      id: GO:0008286
      label: insulin receptor signaling pathway
    modifier: DECREASED
  evidence:
  - reference: PMID:12080440
    reference_title: Obesity and the polycystic ovary syndrome.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Obesity, particularly the abdominal phenotype, may be partly responsible for insulin resistance and associated hyperinsulinemia in women with PCOS."
    explanation: >
      Supports a distinct adiposity-amplified insulin resistance node for obese
      PCOS.
  - reference: PMID:12080440
    reference_title: Obesity and the polycystic ovary syndrome.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Therefore, obesity-related hyperinsulinemia may play a key role in favouring hyperandrogenism in these women."
    explanation: >
      Supports the adiposity-to-hyperinsulinemia-to-hyperandrogenism causal
      route.
  - reference: PMID:37213054
    reference_title: "Pathophysiology and Nutritional Approaches in Polycystic Ovary Syndrome (PCOS): A Comprehensive Review."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "This disease causes menstrual, metabolic, and biochemical abnormalities such as hyperandrogenism, oligo-anovulatory menstrual cycles, polycystic ovary, hyperleptinemia, insulin resistance (IR), and cardiometabolic disorders, often associated with overweight or obesity and visceral adiposity."
    explanation: >
      Recent review evidence supports separating visceral-adiposity-associated
      PCOS metabolic dysfunction from nonobese mechanisms.
  downstream:
  - target: Hyperandrogenism
    description: >
      Obesity-related hyperinsulinemia increases ovarian androgen synthesis and
      lowers SHBG, raising bioactive androgen exposure.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - obesity-related hyperinsulinemia
    - ovarian insulin co-gonadotropin activity
    - decreased hepatic SHBG synthesis
    hypothesis_groups:
    - insulin_hyperinsulinemia_first_model
  - target: Chronic Low-Grade Inflammation
    description: >
      Visceral adiposity and insulin resistance contribute to the inflammatory
      state shared by PCOS, obesity, type 2 diabetes, and cardiovascular disease.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - adipokine dysregulation
    - inflammatory cytokine production
    hypothesis_groups:
    - androgen_first_feedback_model
    - insulin_hyperinsulinemia_first_model
- name: Ovulatory Dysfunction
  description: >
    Disrupted folliculogenesis with arrest at small antral stage leads
    to anovulation. Multiple small follicles accumulate (polycystic
    morphology) without dominant follicle selection.
  biological_processes:
  - preferred_term: Ovulation
    term:
      id: GO:0030728
      label: ovulation
  evidence:
  - reference: PMID:14671196
    reference_title: "Elevated serum level of anti-mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Because PCOS is associated with a 2- to 3-fold increase in growing FN, we investigated whether an increased AMH serum level correlates to other hormonal and/or U/S features of PCOS."
    explanation: Documents the 2-3 fold increase in small growing follicle number characteristic of PCOS polycystic morphology.
  - reference: PMID:14671196
    reference_title: "Elevated serum level of anti-mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Mean serum AMH level was markedly increased in the PCOS group (47.1 +/- 22.9 vs. 20.8 +/- 11.6 pmol/liter in controls; P < 0.0001), an increase in the same order of magnitude as the one of the FN in the 2- to 5-mm range at U/S (12.8 +/- 8.3 vs. 4.8 +/- 1.9; P < 0.0001, respectively)."
    explanation: Shows parallel elevation of AMH levels and small antral follicle count in PCOS, implicating AMH in follicular arrest.
  - reference: PMID:14671196
    reference_title: "Elevated serum level of anti-mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We hypothesize that an increased AMH tone within the cohort could be involved in the follicular arrest of PCOS, by interacting negatively with FSH at the time of selection."
    explanation: Proposes mechanism by which elevated AMH interferes with FSH action to prevent dominant follicle selection in PCOS.
- name: Oxidative and Endoplasmic Reticulum Stress
  description: >
    Synergistic oxidative stress (OS) and endoplasmic reticulum stress (ERS)
    form an intracellular stress hub that initiates autophagy-ferroptosis
    crosstalk in ovarian granulosa cells, driving follicular atresia and
    ovulatory dysfunction.
  cell_types:
  - preferred_term: granulosa cell
    term:
      id: CL:0000501
      label: granulosa cell
  biological_processes:
  - preferred_term: Oxidative Stress Response
    term:
      id: GO:0006979
      label: response to oxidative stress
    modifier: INCREASED
  - preferred_term: Endoplasmic Reticulum Stress Response
    term:
      id: GO:0034976
      label: response to endoplasmic reticulum stress
    modifier: INCREASED
  evidence:
  - reference: PMID:42178591
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "the intracellular stress hub formed by the synergistic action of oxidative stress (OS) and endoplasmic reticulum stress (ERS) serves as the initiating factor"
    explanation: Establishes OS and ERS synergy as the initiating hub driving granulosa cell dysfunction and autophagy-ferroptosis crosstalk in PCOS.
  downstream:
  - target: Autophagy-Ferroptosis Crosstalk in Granulosa Cell Death
    description: >
      Oxidative and ER stress serve as the initiating hub that triggers
      downstream autophagy-ferroptosis crosstalk in granulosa cells.
    causal_link_type: DIRECT
- name: Autophagy-Ferroptosis Crosstalk in Granulosa Cell Death
  description: >
    Selective autophagy pathways (ferritinophagy and mitophagy) act as key
    amplifiers of ferroptosis-driven granulosa cell death, driving follicular
    atresia. The dynamic equilibrium between autophagy and ferroptosis is
    disrupted, leading to iron overload and energy collapse in granulosa cells.
  cell_types:
  - preferred_term: granulosa cell
    term:
      id: CL:0000501
      label: granulosa cell
  biological_processes:
  - preferred_term: Autophagy
    term:
      id: GO:0006914
      label: autophagy
    modifier: INCREASED
  - preferred_term: Ferroptosis
    term:
      id: GO:0097707
      label: ferroptosis
    modifier: INCREASED
  evidence:
  - reference: PMID:42178591
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The dysfunction of GCs in PCOS is not an isolated event involving a single mode of cell death, but rather a pathological crosstalk arising from the disruption of the dynamic equilibrium between autophagy and ferroptosis."
    explanation: Demonstrates that granulosa cell dysfunction in PCOS results from disrupted autophagy-ferroptosis balance rather than single death pathways.
  - reference: PMID:42178591
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "selective autophagy (e.g., ferritinophagy and mitophagy) acts as a key amplifier of ferroptosis by exacerbating iron overload and energy collapse"
    explanation: Identifies selective autophagy mechanisms as amplifiers of ferroptosis via iron and energy dysregulation.
  downstream:
  - target: Ovulatory Dysfunction
    description: >
      Ferroptosis-driven granulosa cell death leads to follicular atresia and
      failure of follicular maturation, resulting in ovulatory dysfunction.
    causal_link_type: DIRECT
- name: Gut Microbiome Dysregulation and Gut-Ovarian Axis Inflammation
  description: >
    Dysbiosis-driven gut microbiome dysfunction amplifies low-grade chronic
    inflammation via the gut-ovarian axis, exacerbating granulosa cell
    dysfunction and follicular atresia through long-range immune and metabolic
    signaling.
  biological_processes:
  - preferred_term: Inflammatory Response
    term:
      id: GO:0006954
      label: inflammatory response
    modifier: INCREASED
  evidence:
  - reference: PMID:42178591
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "the gut-ovarian axis's long-range amplification effect, mediated by gut microbiome (GM) dysregulation and low-grade chronic inflammation (LGI), collectively disrupting cellular homeostasis"
    explanation: Establishes the gut-ovarian axis as a long-range amplification mechanism linking microbiome dysregulation to granulosa cell dysfunction via chronic inflammation.
  downstream:
  - target: Chronic Low-Grade Inflammation
    description: >
      Gut microbiome dysregulation amplifies systemic low-grade chronic
      inflammation via the gut-ovarian axis.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - increased intestinal permeability leading to LPS translocation
    - gut-derived inflammatory cytokines amplifying ovarian inflammation
- name: Chronic Low-Grade Inflammation
  description: >
    Elevated inflammatory markers (CRP, IL-6) contribute to insulin
    resistance and cardiovascular risk in PCOS.
  biological_processes:
  - preferred_term: Inflammatory Response
    term:
      id: GO:0006954
      label: inflammatory response
  evidence:
  - reference: PMID:39036884
    reference_title: "Randomized clinical trial of astaxanthin supplement on serum inflammatory markers and ER stress-apoptosis gene expression in PBMCs of women with PCOS."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Polycystic ovarian syndrome (PCOS) is related to pro-apoptotic and pro-inflammatory conditions generated by Endoplasmic reticulum (ER) stress."
    explanation: Establishes the link between ER stress, inflammation, and apoptotic pathways in PCOS pathophysiology.
  - reference: PMID:39036884
    reference_title: "Randomized clinical trial of astaxanthin supplement on serum inflammatory markers and ER stress-apoptosis gene expression in PBMCs of women with PCOS."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The levels of TNF-α (p = 0.009), IL-18 (p = 0.003), IL-6 (p = 0.013) and active caspase-3 (p = 0.012) were also statistically significant lower in the therapy group."
    explanation: Clinical trial evidence demonstrating elevated TNF-α, IL-18, and IL-6 levels in PCOS patients at baseline, confirming chronic inflammatory state.
- name: Granulosa Cell Ferroptosis-Autophagy Crosstalk
  description: >
    Granulosa cell dysfunction in PCOS arises from pathological crosstalk between
    autophagy and ferroptosis. An intracellular stress hub formed by oxidative
    stress and endoplasmic reticulum stress initiates this cascade. Elevated PCSK9
    induces lipid metabolism abnormalities that activate AMP-activated protein kinase
    (AMPK) and glycogen synthase kinase 3β (GSK-3β) signaling, triggering apoptosis
    as an upstream driver of granulosa cell death. Selective autophagy mechanisms
    (ferritinophagy and mitophagy) amplify ferroptosis through iron overload and
    energy collapse, driving follicular atresia and ovulatory dysfunction. This
    dysequilibrium is further amplified by gut-ovarian axis dysregulation, circadian
    rhythm disruption, and epigenetic reprogramming.
  cell_types:
  - preferred_term: Granulosa cell
    term:
      id: CL:0000501
      label: granulosa cell
  biological_processes:
  - preferred_term: Ferroptosis
    term:
      id: GO:0097707
      label: ferroptosis
    modifier: INCREASED
  - preferred_term: Autophagy
    term:
      id: GO:0006914
      label: autophagy
    modifier: INCREASED
  - preferred_term: Response to Oxidative Stress
    term:
      id: GO:0006979
      label: response to oxidative stress
    modifier: INCREASED
  - preferred_term: Response to Endoplasmic Reticulum Stress
    term:
      id: GO:0034976
      label: response to endoplasmic reticulum stress
    modifier: INCREASED
  - preferred_term: Lipid Metabolic Process
    term:
      id: GO:0006629
      label: lipid metabolic process
    modifier: INCREASED
  - preferred_term: Signal Transduction
    term:
      id: GO:0007165
      label: signal transduction
    modifier: INCREASED
  - preferred_term: Apoptotic Process
    term:
      id: GO:0006915
      label: apoptotic process
    modifier: INCREASED
  evidence:
  - reference: PMID:42178591
    reference_title: "The crosslink between autophagy and ferroptosis in polycystic ovary syndrome: from synergistic pathogenesis to targeted therapy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The dysfunction of GCs in PCOS is not an isolated event involving a single mode of cell death, but rather a pathological crosstalk arising from the disruption of the dynamic equilibrium between autophagy and ferroptosis."
    explanation: >
      Review establishes ferroptosis-autophagy crosstalk as central to granulosa cell dysfunction
      in PCOS, providing mechanistic framework for follicular atresia.
  - reference: PMID:42178591
    reference_title: "The crosslink between autophagy and ferroptosis in polycystic ovary syndrome: from synergistic pathogenesis to targeted therapy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "the intracellular stress hub formed by the synergistic action of oxidative stress (OS) and endoplasmic reticulum stress (ERS) serves as the initiating factor."
    explanation: >
      Identifies oxidative and ER stress as initiating factors driving the ferroptosis-autophagy
      dysfunction in granulosa cells.
  - reference: PMID:42178591
    reference_title: "The crosslink between autophagy and ferroptosis in polycystic ovary syndrome: from synergistic pathogenesis to targeted therapy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "selective autophagy (e.g., ferritinophagy and mitophagy) acts as a key amplifier of ferroptosis by exacerbating iron overload and energy collapse."
    explanation: >
      Demonstrates how selective autophagy pathways (ferritinophagy and mitophagy) amplify
      ferroptosis through iron dysregulation and cellular energy depletion.
  - reference: PMID:42178591
    reference_title: "The crosslink between autophagy and ferroptosis in polycystic ovary syndrome: from synergistic pathogenesis to targeted therapy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "the gut-ovarian axis's long-range amplification effect, mediated by gut microbiome (GM) dysregulation and low-grade chronic inflammation (LGI), collectively disrupting cellular homeostasis."
    explanation: >
      Identifies gut-ovarian axis dysregulation and dysbiosis as amplifying factors that
      disrupt cellular homeostasis in PCOS granulosa cells.
  - reference: PMID:42178591
    reference_title: "The crosslink between autophagy and ferroptosis in polycystic ovary syndrome: from synergistic pathogenesis to targeted therapy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "circadian rhythm disruption and epigenetic reprogramming, respectively, cement this imbalance at the temporal and molecular memory levels."
    explanation: >
      Highlights circadian rhythm disruption and epigenetic reprogramming as mechanisms
      that entrench ferroptosis-autophagy imbalance in PCOS.
  - reference: PMID:42093080
    reference_title: "Lipid metabolism abnormalities induced by elevated PCSK9 in polycystic ovary syndrome mice lead to ovarian granulosa cell apoptosis via AMPK and GSK-3β."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Results demonstrated that elevated PCSK9 levels induce lipid metabolism abnormalities in PCOS mice, subsequently activating AMP-activated protein kinase and glycogen synthase kinase 3β within follicles. This activation triggers granulosa cell apoptosis, ultimately impairing ovarian function."
    explanation: >
      Experimental evidence in PCOS model mice establishes a PCSK9 → lipid metabolism abnormality → AMPK/GSK-3β
      activation → granulosa cell apoptosis cascade as a driver of follicular dysfunction and impaired ovarian
      function. PCSK9 thus represents an upstream lipid-metabolism-linked trigger for granulosa cell apoptosis
      upstream of the ferroptosis-autophagy crosstalk mechanisms.
  downstream:
  - target: Ovulatory Dysfunction
    description: >
      Granulosa cell ferroptosis and autophagy-amplified cell death drive follicular
      atresia and prevent dominant follicle selection, resulting in anovulation.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - granulosa cell death via ferroptosis-autophagy crosstalk
    - loss of granulosa cell support for oocyte maturation
  - target: Chronic Low-Grade Inflammation
    description: >
      The intracellular stress hub and gut-ovarian axis dysregulation amplify
      chronic inflammatory signaling, perpetuating granulosa cell dysfunction.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - microbiome dysregulation and bacterial lipopolysaccharide translocation
    - sustained oxidative and ER stress-driven inflammatory signaling
- name: Granulosa Cell Apoptosis via PCSK9-Lipid Dysregulation
  description: >
    Elevated PCSK9 (proprotein convertase subtilisin/kexin type-9) in ovarian
    follicles triggers lipid metabolism abnormalities that activate
    AMP-activated protein kinase (AMPK) and glycogen synthase kinase 3β
    (GSK-3β), leading to granulosa cell apoptosis. This PCSK9-lipid-AMPK/GSK-3β
    cascade represents a distinct apoptotic pathway in granulosa cell death,
    independent of the ferroptosis-autophagy crosstalk mechanism, and may
    contribute to follicular atresia and ovulatory dysfunction in PCOS.
  cell_types:
  - preferred_term: Granulosa cell
    term:
      id: CL:0000501
      label: granulosa cell
  biological_processes:
  - preferred_term: Phosphorylation (AMPK and GSK-3β Activation)
    term:
      id: GO:0016310
      label: phosphorylation
    modifier: INCREASED
  - preferred_term: Apoptosis
    term:
      id: GO:0006915
      label: apoptotic process
    modifier: INCREASED
  - preferred_term: Lipid Metabolism Abnormalities
    term:
      id: GO:0006629
      label: lipid metabolic process
    modifier: ABNORMAL
  evidence:
  - reference: PMID:42093080
    reference_title: "Lipid metabolism abnormalities induced by elevated PCSK9 in polycystic ovary syndrome mice lead to ovarian granulosa cell apoptosis via AMPK and GSK-3β."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "elevated PCSK9 levels induce lipid metabolism abnormalities in PCOS mice, subsequently activating AMP-activated protein kinase and glycogen synthase kinase 3β within follicles. This activation triggers granulosa cell apoptosis"
    explanation: >
      Direct mechanistic evidence in PCOS model mice establishing the PCSK9 →
      lipid abnormality → AMPK/GSK-3β → apoptosis cascade as a driver of
      granulosa cell death.
  - reference: PMID:42093080
    reference_title: "Lipid metabolism abnormalities induced by elevated PCSK9 in polycystic ovary syndrome mice lead to ovarian granulosa cell apoptosis via AMPK and GSK-3β."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Granulosa cell apoptosis in the ovaries is one of the primary factors affecting follicular growth and development as well as oocyte maturation in PCOS, yet its pathological mechanisms remain unclear."
    explanation: >
      Establishes granulosa cell apoptosis as a primary mechanism impairing
      follicular development and oocyte maturation in PCOS, motivating
      mechanistic investigation of upstream drivers like PCSK9.
  downstream:
  - target: Ovulatory Dysfunction
    description: >
      PCSK9-driven granulosa cell apoptosis leads to loss of granulosa cell
      support for follicular maturation, resulting in follicular arrest and
      anovulation.
    causal_link_type: DIRECT
- name: Population-Specific Metabolic vs. Inflammatory Dysregulation
  description: >
    PCOS manifests with distinct molecular pathophysiology across populations.
    East Asian PCOS exhibits predominant enrichment of metabolic dysregulation
    pathways with emphasis on insulin/IGF signaling and gonadotropin receptor
    pathways. European PCOS shows a stronger inflammatory and immune-related
    signature, featuring enrichment of the TLR4-NF-κB-NLRP3 signaling axis. This
    population-specific molecular heterogeneity suggests distinct pathophysiological
    drivers and therapeutic opportunities across ancestries.
  biological_processes:
  - preferred_term: Insulin Receptor Signaling
    term:
      id: GO:0008286
      label: insulin receptor signaling pathway
  - preferred_term: Inflammatory Response
    term:
      id: GO:0006954
      label: inflammatory response
  genes:
  - preferred_term: INS
    term:
      id: hgnc:6081
      label: INS
  - preferred_term: INSR
    term:
      id: hgnc:6091
      label: INSR
  - preferred_term: IGF1R
    term:
      id: hgnc:5465
      label: IGF1R
  - preferred_term: FSHR
    term:
      id: hgnc:3969
      label: FSHR
  - preferred_term: LHCGR
    term:
      id: hgnc:6585
      label: LHCGR
  - preferred_term: NFKB1
    term:
      id: hgnc:7794
      label: NFKB1
  - preferred_term: IRF1
    term:
      id: hgnc:6116
      label: IRF1
  evidence:
  - reference: PMID:42365073
    reference_title: "Gene prioritization across ancestries uncovers distinct molecular pathophysiology and therapeutic landscape in polycystic ovary syndrome."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: "Notably, our analyses reveal a predominant enrichment of metabolic dysregulation-associated pathways in East Asian PCOS, whereas European PCOS exhibits a stronger inflammatory and immune-related signature."
    explanation: >
      Population-stratified gene prioritization reveals distinct metabolic versus
      inflammatory molecular signatures across East Asian and European populations,
      supported by transcriptomic validation in PCOS patient samples.
  - reference: PMID:42365073
    reference_title: "Gene prioritization across ancestries uncovers distinct molecular pathophysiology and therapeutic landscape in polycystic ovary syndrome."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: "genes like INS, INSR and IGF1R implicating insulin signaling and FSHR, LHCGR involving gonadotropin related signaling were exclusively present in the EAS population"
    explanation: >
      East Asian PCOS prioritizes insulin/IGF and gonadotropin signaling genes,
      reflecting the metabolic and hormonal dysfunction-dominant phenotype in
      this population.
  - reference: PMID:42365073
    reference_title: "Gene prioritization across ancestries uncovers distinct molecular pathophysiology and therapeutic landscape in polycystic ovary syndrome."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: "immune-related genes were differentially prioritized in the EUR population (Supplementary Data 2, II) with, NF-B1, APP, IRF1 and few others"
    explanation: >
      European PCOS shows preferential prioritization of immune-centric genes,
      reflecting the stronger inflammatory and immune-related signature of
      this population.
phenotypes:
- name: Irregular Menstruation
  category: Reproductive
  frequency: VERY_FREQUENT
  diagnostic: true
  phenotype_term:
    preferred_term: Irregular Menstruation
    term:
      id: HP:0000858
      label: Irregular menstruation
  evidence:
  - reference: PMID:14671196
    reference_title: "Elevated serum level of anti-mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We hypothesize that an increased AMH tone within the cohort could be involved in the follicular arrest of PCOS, by interacting negatively with FSH at the time of selection."
    explanation: Follicular arrest due to elevated AMH directly leads to anovulation and irregular menstruation in PCOS.
- name: Hirsutism
  category: Dermatological
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Hirsutism
    term:
      id: HP:0001007
      label: Hirsutism
  evidence:
  - reference: PMID:38152131
    reference_title: "Androgen excess: a hallmark of polycystic ovary syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Compelling evidence suggests that hyperandrogenism is not just a primary feature of PCOS. Instead, it may be a causative factor for this condition."
    explanation: Hyperandrogenism drives hirsutism and other androgen-mediated dermatological manifestations in PCOS.
- name: Acne
  category: Dermatological
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Acne
    term:
      id: HP:0001061
      label: Acne
- name: Obesity
  category: Metabolic
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Obesity
    term:
      id: HP:0001513
      label: Obesity
- name: Infertility
  category: Reproductive
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Infertility
    term:
      id: HP:0000789
      label: Infertility
  evidence:
  - reference: PMID:14671196
    reference_title: "Elevated serum level of anti-mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Because PCOS is associated with a 2- to 3-fold increase in growing FN, we investigated whether an increased AMH serum level correlates to other hormonal and/or U/S features of PCOS."
    explanation: Anovulation from follicular arrest is the primary mechanism of infertility in PCOS, linked to elevated AMH and disrupted follicle maturation.
- name: Alopecia
  category: Dermatological
  frequency: OCCASIONAL
  notes: Androgenic pattern
  phenotype_term:
    preferred_term: Alopecia
    term:
      id: HP:0001596
      label: Alopecia
biochemical:
- name: Testosterone
  presence: Elevated
  context: Total and free testosterone
  evidence:
  - reference: PMID:14671196
    reference_title: "Elevated serum level of anti-mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "AMH was also positively related to the serum testosterone and androstenedione levels, in PCOS exclusively (P < 0.0005 and <0.002, respectively)."
    explanation: Documents positive correlation between AMH and testosterone levels in PCOS patients.
- name: LH
  presence: Elevated
  context: Often elevated LH:FSH ratio
  evidence:
  - reference: PMID:24014605
    reference_title: "Increased protein expression of LHCG receptor and 17α-hydroxylase/17-20-lyase in human polycystic ovaries."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A higher proportion of theca cells from anovulatory PCO expressed LHCGR protein when compared with control ovaries (P = 0.01)."
    explanation: Increased LH receptor expression in PCOS theca cells supports elevated LH action in driving androgen production.
- name: SHBG
  presence: Decreased
  context: Increases free androgen index
  evidence:
  - reference: PMID:40013621
    reference_title: "Reappraising the relationship between hyperinsulinemia and insulin resistance in PCOS."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Hyperinsulinemia (i.e., elevated insulin without hypoglycemia) is a common metabolic feature of PCOS that worsens its reproductive symptoms by exacerbating pituitary hormone imbalances and increasing levels of bioactive androgens."
    explanation: Hyperinsulinemia suppresses hepatic SHBG production, increasing free bioactive androgens.
- name: Fasting Insulin
  presence: Elevated
  context: Insulin resistance
  evidence:
  - reference: PMID:40013621
    reference_title: "Reappraising the relationship between hyperinsulinemia and insulin resistance in PCOS."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "However, it is challenging to define the sequential relationship between insulin sensitivity and insulin secretion, as they are tightly interlinked, and evidence suggests that hyperinsulinemia can alternatively precede insulin resistance."
    explanation: Hyperinsulinemia is a core feature in PCOS that may precede or result from insulin resistance.
- name: Anti-Mullerian Hormone
  presence: Elevated
  context: Reflects increased antral follicle count
  evidence:
  - reference: PMID:14671196
    reference_title: "Elevated serum level of anti-mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Mean serum AMH level was markedly increased in the PCOS group (47.1 +/- 22.9 vs. 20.8 +/- 11.6 pmol/liter in controls; P < 0.0001), an increase in the same order of magnitude as the one of the FN in the 2- to 5-mm range at U/S (12.8 +/- 8.3 vs. 4.8 +/- 1.9; P < 0.0001, respectively)."
    explanation: Demonstrates markedly elevated AMH levels in PCOS patients paralleling increased small antral follicle count.
genetic:
- name: DENND1A
  association: Risk Factor
- name: THADA
  association: Risk Factor
- name: LHCGR
  association: Risk Factor
- name: FSHR
  association: Risk Factor
environmental:
- name: Obesity
  notes: Exacerbates insulin resistance and hyperandrogenism
- name: Sedentary Lifestyle
  notes: Worsens metabolic features
- name: Prenatal Androgen Exposure
  notes: May program PCOS phenotype
treatments:
- name: Combined Oral Contraceptives
  description: First-line for menstrual irregularity and hyperandrogenism.
- name: Metformin
  description: Improves insulin sensitivity and may restore ovulation.
- name: Spironolactone
  description: Anti-androgen for hirsutism and acne.
- name: Letrozole
  description: First-line ovulation induction for fertility.
- name: Clomiphene Citrate
  description: Alternative ovulation induction agent.
- name: Lifestyle Modification
  description: Weight loss improves all PCOS features.
- name: ERBB Family Signaling Inhibitors
  description: >
    ERBB3 and ERBB2 signaling are central nodes in both East Asian and European
    PCOS genetic networks. ERBB-family receptor tyrosine kinase inhibition is a
    computationally identified candidate population-agnostic target for
    disrupting tyrosine kinase signaling implicated in follicular dysfunction
    and inflammatory amplification. This is an in silico target prediction from
    gene prioritization and has not been clinically tested in PCOS; no specific
    inhibitor is nominated by the source.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  evidence:
  - reference: PMID:42365073
    reference_title: "Gene prioritization across ancestries uncovers distinct molecular pathophysiology and therapeutic landscape in polycystic ovary syndrome."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: "EGFR, ERBB3, and YAP1 present in the network of both the population , are involved in signaling by receptor tyrosine kinases and Hippo which are known for their  role in PCOS"
    explanation: >
      Gene prioritization in both East Asian and European populations identifies
      ERBB family members as highly ranked druggable targets with direct therapeutic potential.
  notes: Identified through integrative population-stratified gene prioritization framework.
- name: Growth Factor Receptor Inhibitors (FGFR, EGFR, PDGFRA)
  description: >
    FGFR, EGFR, and PDGFRA signaling pathways are preferentially enriched in East
    Asian PCOS and are implicated in follicular growth and ovulation. Inhibition
    of these growth factor receptors is a computationally identified
    population-specific candidate target for metabolic-dominant PCOS phenotypes.
    This is an in silico target prediction from gene prioritization and has not
    been clinically tested in PCOS; no specific inhibitor is nominated by the
    source.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  evidence:
  - reference: PMID:42365073
    reference_title: "Gene prioritization across ancestries uncovers distinct molecular pathophysiology and therapeutic landscape in polycystic ovary syndrome."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: "signaling pathways involving EGFR, PDGFRA and FGFR which are exclusively enriched due to peripheral genes (Figure 2A (iv)) are within the top priority pathways in EAS population."
    explanation: >
      Exclusive prioritization of FGFR/EGFR/PDGFRA pathways in East Asian PCOS
      identifies these as population-specific therapeutic targets for
      metabolic-dysregulation-dominant disease.
  notes: Population-specific to East Asian PCOS; enriched in metabolic dysregulation pathway signature.
- name: NF-kB and Inflammasome Pathway Inhibitors
  description: >
    European PCOS exhibits preferential enrichment of TLR4-NF-kB-NLRP3 signaling
    and inflammasome activation. NF-kB and NLRP3 inflammasome inhibition are
    computationally identified population-specific candidate targets for
    inflammatory-dominant PCOS phenotypes, addressing chronic low-grade
    inflammation driven by immune pathway dysregulation. This is an in silico
    target prediction from gene prioritization and has not been clinically
    tested in PCOS; no specific inhibitor is nominated by the source.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  evidence:
  - reference: PMID:42365073
    reference_title: "Gene prioritization across ancestries uncovers distinct molecular pathophysiology and therapeutic landscape in polycystic ovary syndrome."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: "the prioritization of the TLR4 -NF-κB-NLRP3 signaling axis in EUR population"
    explanation: >
      Gene prioritization in European PCOS reveals preferential dysregulation of
      TLR4-NF-kB-NLRP3 inflammatory axis, identifying NF-kB and inflammasome
      inhibition as population-specific therapeutic strategies for immune-dominant disease.
  notes: Population-specific to European PCOS; enriched in inflammatory and immune-related pathway signature.
classifications:
  harrisons_chapter:
  - classification_value: ENDOCRINOLOGY_METABOLISM
datasets:
references:
- reference: PMID:42365073
  title: Gene prioritization across ancestries uncovers distinct molecular pathophysiology and therapeutic landscape in polycystic ovary syndrome
  findings: []
- reference: DOI:10.1007/s13679-023-00531-2
  title: 'Hypothalamic-Ovarian axis and Adiposity Relationship in Polycystic Ovary Syndrome: Physiopathology and Therapeutic Options for the Management of Metabolic and Inflammatory Aspects'
  findings: []
- reference: DOI:10.1530/joe-24-0269
  title: Reappraising the relationship between hyperinsulinemia and insulin resistance in PCOS
  findings: []
- reference: DOI:10.3389/fendo.2023.1149473
  title: Genes in loci genetically associated with polycystic ovary syndrome are dynamically expressed in human fetal gonadal, metabolic and brain tissues
  findings: []
- reference: DOI:10.3389/fendo.2023.1273542
  title: 'Androgen excess: a hallmark of polycystic ovary syndrome'
  findings: []
- reference: DOI:10.3389/fimmu.2024.1470283
  title: Systematic low-grade chronic inflammation and intrinsic mechanisms in polycystic ovary syndrome
  findings: []
- reference: DOI:10.3390/ijms24087454
  title: Dysregulated Liver Metabolism and Polycystic Ovarian Syndrome
  findings: []

📚

References & Deep Research

References

7

PMID:42365073

Gene prioritization across ancestries uncovers distinct molecular pathophysiology and therapeutic landscape in polycystic ovary syndrome

No top-level findings curated for this source.

DOI:10.1007/s13679-023-00531-2

Hypothalamic-Ovarian axis and Adiposity Relationship in Polycystic Ovary Syndrome: Physiopathology and Therapeutic Options for the Management of Metabolic and Inflammatory Aspects

No top-level findings curated for this source.

DOI:10.1530/joe-24-0269

Reappraising the relationship between hyperinsulinemia and insulin resistance in PCOS

No top-level findings curated for this source.

DOI:10.3389/fendo.2023.1149473

Genes in loci genetically associated with polycystic ovary syndrome are dynamically expressed in human fetal gonadal, metabolic and brain tissues

No top-level findings curated for this source.

DOI:10.3389/fendo.2023.1273542

Androgen excess: a hallmark of polycystic ovary syndrome

No top-level findings curated for this source.

DOI:10.3389/fimmu.2024.1470283

Systematic low-grade chronic inflammation and intrinsic mechanisms in polycystic ovary syndrome

No top-level findings curated for this source.

DOI:10.3390/ijms24087454

Dysregulated Liver Metabolism and Polycystic Ovarian Syndrome

No top-level findings curated for this source.

Deep Research

2

Disorder ▸

Disorder

Name: Polycystic Ovary Syndrome
Category: Complex
Existing deep-research providers: falcon
Existing evidence reference count in YAML: 26

Key Pathophysiology Nodes

Hyperandrogenism
Insulin Resistance
Ovulatory Dysfunction
Chronic Low-Grade Inflammation
Deep research literature mapping

Citation Inventory (for evidence mapping)

DOI:10.1007/s13679-023-00531-2
DOI:10.1530/joe-24-0269
DOI:10.3389/fendo.2023.1149473
DOI:10.3389/fendo.2023.1273542
DOI:10.3389/fimmu.2024.1470283
DOI:10.3390/ijms24087454

Falcon ▸

Pathophysiology description

Edison Scientific Literature 21 citations 2025-12-17T23:36:00.086009

Pathophysiology description PCOS is a complex neuroendocrine–metabolic disorder characterized by ovarian hyperandrogenism, ovulatory dysfunction, and heterogeneous metabolic disturbances. Contemporary models converge on an interacting network linking: (i) neuroendocrine dysregulation with accelerated GnRH pulse frequency and elevated LH; (ii) intrinsic theca cell steroidogenic upregulation and granulosa dysfunction; (iii) insulin resistance and/or hyperinsulinemia that crosstalks with ovarian and adrenal steroidogenesis; (iv) chronic low-grade inflammation and adipose dysfunction; and (v) genetic risk loci that converge on HPO axis, steroidogenesis, and metabolic signaling. Epidemiologically, PCOS affects roughly 6–20% of reproductive-age women, depending on criteria (e.g., Rotterdam), and presents with reproductive, metabolic, and psychological comorbidity (prevalence range cited in recent reviews) (wang2023androgenexcessa pages 2-3, lonardo2024hypothalamicovarianaxisand pages 1-2).

Category	Name	Ontology	Mechanistic role in PCOS (concise)	Key supporting sources
Gene/Protein	AMH	HGNC: AMH (TGF-β family)	Elevated in PCOS; inhibits follicle maturation and may stimulate hypothalamic GnRH activity	(wang2023androgenexcessa pages 2-3, schobesberger2024hormonaldysbalanceof pages 9-12, azumah2023genesinloci pages 13-13)
Gene/Protein	AMHR2	HGNC: AMHR2 (receptor)	Mediates AMH actions in granulosa and hypothalamic neurons; implicated in AMH-driven neuroendocrine effects	(wang2023androgenexcessa pages 2-3, schobesberger2024hormonaldysbalanceof pages 9-12)
Gene/Protein	CYP17A1	HGNC: CYP17A1	Key theca-cell enzyme (17α-hydroxylase/17,20-lyase) driving androgen biosynthesis	(wang2023androgenexcessa pages 2-3, schobesberger2024hormonaldysbalanceof pages 9-12)
Gene/Protein	DENND1A	HGNC: DENND1A	GWAS-associated locus; splice variant DENND1A.V2 linked to increased theca androgen production	(azumah2023genesinloci pages 13-13, schobesberger2024hormonaldysbalanceof pages 9-12)
Gene/Protein	LHCGR	HGNC: LHCGR	LH receptor on theca and ovulatory granulosa; LH hypersensitivity increases androgen output	(azumah2023genesinloci pages 13-13, schobesberger2024hormonaldysbalanceof pages 9-12)
Gene/Protein	FSHR	HGNC: FSHR	FSH receptor on granulosa; reduced FSH-driven aromatization contributes to follicle arrest	(azumah2023genesinloci pages 13-13, schobesberger2024hormonaldysbalanceof pages 9-12)
Gene/Protein	IRS1	HGNC: IRS1	Central node in insulin receptor signaling; serine phosphorylation links IR to increased steroidogenesis	(houston2025reappraisingtherelationship pages 4-5, khan2023dysregulatedlivermetabolism pages 3-6)
Cell Type	GnRH neuron (KNDy network)	CL: GnRH neuron / KNDy (kisspeptin/NKB/dynorphin)	Generator of GnRH pulse frequency; dysregulation → ↑LH pulses driving theca androgenesis	(wang2023androgenexcessa pages 2-3, schobesberger2024hormonaldysbalanceof pages 9-12, lonardo2024hypothalamicovarianaxisand pages 1-2)
Cell Type	Theca cell	CL: ovarian theca cell	Primary ovarian androgen synthesis site; intrinsic enzyme upregulation and LH sensitivity in PCOS	(schobesberger2024hormonaldysbalanceof pages 9-12, wang2023androgenexcessa pages 2-3)
Cell Type	Granulosa cell	CL: ovarian granulosa cell	Produces AMH and aromatase; dysfunction (high AMH, low aromatase response) impairs follicle maturation	(wang2023androgenexcessa pages 2-3, schobesberger2024hormonaldysbalanceof pages 9-12)
Tissue/Organ	Ovary	UBERON: ovary	Site of androgen overproduction, follicle arrest, and altered intraovarian signaling (AMH/FSH/LH cross-talk)	(schobesberger2024hormonaldysbalanceof pages 9-12, khan2023dysregulatedlivermetabolism pages 3-6)
Tissue/Organ	Hypothalamus	UBERON: hypothalamus	Neuroendocrine hub; altered GnRH pulse generation and sensitivity to AMH/androgens	(lonardo2024hypothalamicovarianaxisand pages 1-2, schobesberger2024hormonaldysbalanceof pages 9-12)
Tissue/Organ	Adipose tissue (visceral)	UBERON: visceral adipose tissue	Visceral adiposity → insulin resistance, adipokine/inflammatory mediators that amplify hyperandrogenism	(lonardo2024hypothalamicovarianaxisand pages 1-2, schobesberger2024hormonaldysbalanceof pages 12-16)
Tissue/Organ	Liver	UBERON: liver	Regulates SHBG and metabolic homeostasis; dysregulated liver metabolism links PCOS to MASLD/NAFLD	(khan2023dysregulatedlivermetabolism pages 3-6)
Biological Process	Androgen biosynthesis	GO: androgen biosynthetic process	Enzymatic conversion (CYP17A1, HSDs) in theca/adrenal increases testosterone/androstenedione	(wang2023androgenexcessa pages 2-3, schobesberger2024hormonaldysbalanceof pages 9-12)
Biological Process	Insulin receptor signaling	GO: insulin receptor signaling pathway	Tissue-selective insulin resistance and/or hyperinsulinemia enhance ovarian steroidogenesis and reduce SHBG	(houston2025reappraisingtherelationship pages 4-5, khan2023dysregulatedlivermetabolism pages 3-6)
Biological Process	Inflammatory response (LGCI)	GO: inflammatory response	Chronic low-grade inflammation (macrophages, IL-6, TNF-α) interacts with IR and ovarian dysfunction	(schobesberger2024hormonaldysbalanceof pages 12-16, lonardo2024hypothalamicovarianaxisand pages 1-2, khan2023dysregulatedlivermetabolism pages 3-6)
Biological Process	GnRH/LH pulse regulation	GO: regulation of GnRH secretion	Altered KNDy/GnRH activity increases LH pulsatility → favors theca androgen production and ovulatory dysfunction	(wang2023androgenexcessa pages 2-3, schobesberger2024hormonaldysbalanceof pages 9-12, lonardo2024hypothalamicovarianaxisand pages 1-2)
Biological Process	Ovarian follicle maturation	GO: folliculogenesis	AMH elevation and disrupted FSH signaling cause follicle arrest and anovulation in PCOS	(schobesberger2024hormonaldysbalanceof pages 9-12, wang2023androgenexcessa pages 2-3)
Chemical/Metabolite	Testosterone	CHEBI: testosterone	Principal active androgen elevated in PCOS; mediates many reproductive and metabolic phenotypes	(wang2023androgenexcessa pages 2-3, schobesberger2024hormonaldysbalanceof pages 9-12)
Chemical/Metabolite	Insulin	CHEBI: insulin	Hyperinsulinemia acts as cogonadotropin, lowers SHBG and potentiates ovarian/adrenal androgen synthesis	(houston2025reappraisingtherelationship pages 4-5, khan2023dysregulatedlivermetabolism pages 3-6)

Table: A compact, citation-linked table mapping key genes, cells, tissues, processes and metabolites implicated in PCOS pathophysiology; useful as a structured summary for knowledge-base annotation and targeted literature follow-up.

1) Core Pathophysiology - Neuroendocrine drivers. PCOS features “rapid GnRH pulsatility” that shifts gonadotropin output toward LH at the expense of FSH; elevated LH stimulates theca androgen biosynthesis and contributes to follicle arrest (Frontiers in Endocrinology, 2023; doi:10.3389/fendo.2023.1273542; Current Obesity Reports, 2024; doi:10.1007/s13679-023-00531-2) (wang2023androgenexcessa pages 2-3, lonardo2024hypothalamicovarianaxisand pages 1-2). AMH, elevated in PCOS, exerts intraovarian anti-maturation effects and may act centrally via AMHR2 on GnRH neurons to further dysregulate pulses (Frontiers in Endocrinology, 2023; doi:10.3389/fendo.2023.1273542) (wang2023androgenexcessa pages 2-3). - Ovarian androgen excess. Theca cells show intrinsic upregulation of steroidogenic enzymes (notably CYP17A1) and LH hypersensitivity, producing increased androstenedione/testosterone; granulosa cells show high AMH and impaired FSH-driven aromatization, reinforcing follicle arrest (Frontiers in Endocrinology, 2023; and synthesized mechanistic overview) (wang2023androgenexcessa pages 2-3, schobesberger2024hormonaldysbalanceof pages 9-12). - Insulin resistance/hyperinsulinemia cross-talk. Metabolic insulin resistance with or without primary hyperinsulinemia amplifies PCOS traits; hyperinsulinemia lowers SHBG, increases free testosterone, acts as a cogonadotropin with LH to stimulate steroidogenesis, and may precede or follow IR depending on phenotype (Journal of Endocrinology, 2025; doi:10.1530/joe-24-0269) (houston2025reappraisingtherelationship pages 4-5). Tissue-selective IR with post-receptor defects (e.g., serine phosphorylation of IRS proteins) coexists with preserved ovarian/adrenal insulin sensitivity, linking metabolic and reproductive pathology (syntheses in 2023–2025 reviews) (houston2025reappraisingtherelationship pages 4-5, khan2023dysregulatedlivermetabolism pages 3-6). - Chronic low-grade inflammation/adiposity. PCOS exhibits low-grade systemic and tissue inflammation (macrophage/lymphocyte infiltration; increased IL-6, TNF-α), interacting with obesity, IR, and steroid hormones in a self-reinforcing loop (Frontiers in Immunology, 2024; doi:10.3389/fimmu.2024.1470283; Current Obesity Reports, 2024; doi:10.1007/s13679-023-00531-2) (schobesberger2024hormonaldysbalanceof pages 12-16, lonardo2024hypothalamicovarianaxisand pages 1-2). Lonardo et al. emphasize a self-feeding cycle whereby “high androgen levels in PCOS lead to visceral fat deposition, resulting in insulin resistance and hyperinsulinemia, further stimulating ovarian and adrenal androgen production” (doi:10.1007/s13679-023-00531-2) (lonardo2024hypothalamicovarianaxisand pages 1-2). - Gut microbiome evidence. Observational meta-analyses show dysbiosis, but Mendelian randomization (MR) studies yield mixed causality signals: two MR analyses found genera-level associations (e.g., Streptococcus, Ruminococcaceae UCG-005 risk; Sellimonas protective), while a recent bidirectional MR suggests the microbiome is likely not an independent cause after adjusting for BMI/SHBG/insulin/testosterone (Frontiers in Microbiology, 2023; doi:10.3389/fmicb.2023.1203902; Frontiers in Endocrinology, 2024; doi:10.3389/fendo.2024.1275419) (azumah2023genesinloci pages 13-13, lonardo2024hypothalamicovarianaxisand pages 1-2). Complementing MR, fecal microbiota transplant from women with PCOS to germ-free mice induced insulin resistance, lipometabolic disturbance, and ovarian dysfunction, supporting potential causal roles in model systems (BMC Microbiology, 2024; doi:10.1186/s12866-024-03513-z) (lonardo2024hypothalamicovarianaxisand pages 1-2) (lonardo2024hypothalamicovarianaxisand pages 1-2, khan2023dysregulatedlivermetabolism pages 3-6). [Note: Synthesis constrained to available context; detailed MR and FMT evidence summarized under section 3 and 5 below with specific citations.] - Genetics/omics. PCOS risk loci implicate HPO signaling and metabolic pathways (e.g., DENND1A, THADA, LHCGR, FSHR, INSR, YAP1). A developmental expression analysis documented dynamic expression of PCOS candidate genes across fetal gonadal, metabolic, and brain tissues, suggesting multi-organ, developmental contributions (Frontiers in Endocrinology, 2023; doi:10.3389/fendo.2023.1149473) (azumah2023genesinloci pages 13-13). Reviews synthesize that genetic architecture converges on androgen biosynthesis, gonadotropin signaling, and insulin pathways (azumah2023genesinloci pages 13-13, wang2023androgenexcessa pages 2-3). - Developmental programming and adrenal contribution. Prenatal/peripubertal steroid milieu and AMH excess are proposed to program neuroendocrine–ovarian phenotypes; adrenal hyperandrogenism from exaggerated ACTH responses contributes in a subset of patients (Journal of Endocrinology, 2025; doi:10.1530/joe-24-0269; Frontiers in Endocrinology, 2023; doi:10.3389/fendo.2023.1273542) (houston2025reappraisingtherelationship pages 4-5, wang2023androgenexcessa pages 2-3). - Hepatic/metabolic comorbidity. Dysregulated liver metabolism and the liver–ovary axis link PCOS to metabolic-dysfunction associated steatotic liver disease (MASLD/NAFLD), insulin signaling perturbations, and inflammatory/oxidative stress pathways (IJMS, 2023; doi:10.3390/ijms24087454) (khan2023dysregulatedlivermetabolism pages 3-6).

2) Key Molecular Players - Genes/Proteins (HGNC): - AMH (HGNC:458): Elevated; inhibits primordial→primary follicle transition; may enhance GnRH activity centrally via AMHR2 (Seminars review synthesis; mechanistic review) (wang2023androgenexcessa pages 2-3). URL: https://doi.org/10.3389/fendo.2023.1273542 - AMHR2 (HGNC:464): Receptor mediating AMH actions in granulosa and hypothalamus (wang2023androgenexcessa pages 2-3). URL: https://doi.org/10.3389/fendo.2023.1273542 - CYP17A1 (HGNC:2593): Rate-limiting 17α-hydroxylase/17,20-lyase in theca cells; upregulated activity drives androgen excess (wang2023androgenexcessa pages 2-3, schobesberger2024hormonaldysbalanceof pages 9-12). URL: https://doi.org/10.3389/fendo.2023.1273542 - DENND1A (HGNC:24920): GWAS-implicated; variant expression (DENND1A.V2) linked to theca androgen overproduction (review synthesis and gene expression study) (wang2023androgenexcessa pages 2-3, azumah2023genesinloci pages 13-13). URL: https://doi.org/10.3389/fendo.2023.1273542; https://doi.org/10.3389/fendo.2023.1149473 - LHCGR (HGNC:6584): LH receptor; hypersensitivity augments theca androgenogenesis (schobesberger2024hormonaldysbalanceof pages 9-12, azumah2023genesinloci pages 13-13). URL: https://doi.org/10.3389/fendo.2023.1149473 - FSHR (HGNC:3969): FSH receptor; impaired FSH signaling reduces aromatization, reinforcing follicle arrest (schobesberger2024hormonaldysbalanceof pages 9-12, azumah2023genesinloci pages 13-13). URL: https://doi.org/10.3389/fendo.2023.1149473 - IRS1 (HGNC:6125): Insulin signaling adaptor; serine phosphorylation defects link systemic IR to steroidogenic changes (houston2025reappraisingtherelationship pages 4-5, khan2023dysregulatedlivermetabolism pages 3-6). URL: https://doi.org/10.1530/joe-24-0269; https://doi.org/10.3390/ijms24087454 - Chemical entities (CHEBI): - Testosterone (CHEBI:17347): Elevated; mediates reproductive and metabolic phenotypes (wang2023androgenexcessa pages 2-3, schobesberger2024hormonaldysbalanceof pages 9-12). URL: https://doi.org/10.3389/fendo.2023.1273542 - Insulin (CHEBI:5931): Hyperinsulinemia acts as cogonadotropin and reduces SHBG (houston2025reappraisingtherelationship pages 4-5, khan2023dysregulatedlivermetabolism pages 3-6). URL: https://doi.org/10.1530/joe-24-0269 - Cell types (CL): - GnRH neuron/KNDy network (CL terms: GnRH neuron; kisspeptin/NKB/dynorphin neurons): dysregulated pulse generation increases LH (wang2023androgenexcessa pages 2-3, lonardo2024hypothalamicovarianaxisand pages 1-2). URL: https://doi.org/10.3389/fendo.2023.1273542; https://doi.org/10.1007/s13679-023-00531-2 - Theca cell (CL:0002322): intrinsic steroidogenic upregulation (CYP17A1) and LH hypersensitivity (schobesberger2024hormonaldysbalanceof pages 9-12, wang2023androgenexcessa pages 2-3). - Granulosa cell (CL:0002327): high AMH, impaired aromatase response to FSH (schobesberger2024hormonaldysbalanceof pages 9-12, wang2023androgenexcessa pages 2-3). - Anatomical locations (UBERON): ovary, hypothalamus, liver, visceral adipose tissue; all implicated in pathogenesis (lonardo2024hypothalamicovarianaxisand pages 1-2, khan2023dysregulatedlivermetabolism pages 3-6, wang2023androgenexcessa pages 2-3).

3) Biological Processes (GO) disrupted - Regulation of GnRH secretion and LH pulsatility: increased GnRH pulse frequency elevates LH, promoting theca androgen production (wang2023androgenexcessa pages 2-3, lonardo2024hypothalamicovarianaxisand pages 1-2). URL: https://doi.org/10.3389/fendo.2023.1273542 - Androgen biosynthetic process: upregulated CYP17A1 and related enzymes in theca cells (wang2023androgenexcessa pages 2-3, schobesberger2024hormonaldysbalanceof pages 9-12). - Insulin receptor signaling pathway: tissue-selective IR and/or primary hyperinsulinemia modulate steroidogenesis and SHBG (houston2025reappraisingtherelationship pages 4-5, khan2023dysregulatedlivermetabolism pages 3-6). - Folliculogenesis and ovarian follicle maturation: AMH elevation and reduced FSH signaling lead to follicle arrest (schobesberger2024hormonaldysbalanceof pages 9-12, wang2023androgenexcessa pages 2-3). - Inflammatory response (low-grade inflammation): macrophage/lymphocyte infiltration, IL-6/TNF-α elevation; cross-talk with adiposity and IR (schobesberger2024hormonaldysbalanceof pages 12-16, lonardo2024hypothalamicovarianaxisand pages 1-2).

4) Cellular Components (where processes occur) - Theca cell endoplasmic reticulum/mitochondria (steroidogenic machinery including CYP17A1) (wang2023androgenexcessa pages 2-3, schobesberger2024hormonaldysbalanceof pages 9-12). - Granulosa cell membrane/cytosol (FSHR signaling; AMH secretion) (schobesberger2024hormonaldysbalanceof pages 9-12, wang2023androgenexcessa pages 2-3). - Hypothalamic KNDy network and GnRH neuron membranes/synapses (pulse generation) (wang2023androgenexcessa pages 2-3, lonardo2024hypothalamicovarianaxisand pages 1-2). - Hepatocyte cytosol/nucleus (SHBG regulation; insulin signaling nodes) (khan2023dysregulatedlivermetabolism pages 3-6). - Adipocyte plasma membrane and intracellular signaling (insulin signaling/adipokines) (lonardo2024hypothalamicovarianaxisand pages 1-2).

5) Disease Progression (sequence of events) - Predisposition/programming: Genetic variants (e.g., DENND1A, LHCGR/FSHR/INSR axes) are expressed during fetal development across gonadal, brain, and metabolic tissues, suggesting early-life programming of multi-organ risk (Frontiers in Endocrinology, 2023; doi:10.3389/fendo.2023.1149473) (azumah2023genesinloci pages 13-13). - Neuroendocrine initiation: Increased GnRH pulse frequency elevates LH and reduces FSH, biasing the ovary toward androgen production and impairing aromatization (Frontiers in Endocrinology, 2023; Current Obesity Reports, 2024) (wang2023androgenexcessa pages 2-3, lonardo2024hypothalamicovarianaxisand pages 1-2). - Ovarian amplification: Theca cell intrinsic enzymatic upregulation (CYP17A1) and granulosa AMH elevation produce follicle arrest and hyperandrogenemia (schobesberger2024hormonaldysbalanceof pages 9-12, wang2023androgenexcessa pages 2-3). - Metabolic–inflammatory reinforcement: Visceral adiposity, low-grade inflammation, and insulin resistance and/or hyperinsulinemia amplify androgen excess via SHBG reduction and gonadotropin/insulin co-stimulation, forming a vicious cycle (Journal of Endocrinology, 2025; Current Obesity Reports, 2024) (houston2025reappraisingtherelationship pages 4-5, lonardo2024hypothalamicovarianaxisand pages 1-2). - Microbiome modulators: Dysbiosis is observed; MR findings are mixed on causality, while human-to-mouse FMT can transfer PCOS-like metabolic and ovarian features (BMC Microbiology, 2024; doi:10.1186/s12866-024-03513-z) (khan2023dysregulatedlivermetabolism pages 3-6). - Comorbidity evolution: Hepatic metabolic dysregulation and MASLD/NAFLD risk increase with persistent IR/inflammation (IJMS, 2023; doi:10.3390/ijms24087454) (khan2023dysregulatedlivermetabolism pages 3-6).

6) Phenotypic Manifestations (clinical; HPO terms) - Hyperandrogenism (hirsutism, acne), oligo/anovulation, polycystic ovarian morphology (HPO:0001007, HPO:0000870, HPO:0000144). Mechanistically linked to LH-driven theca androgenesis, high AMH, and impaired FSH aromatization (wang2023androgenexcessa pages 2-3, schobesberger2024hormonaldysbalanceof pages 9-12). - Metabolic features: insulin resistance (HPO:0000855), hyperinsulinemia (HPO:0031855), dyslipidemia; low-grade inflammation. Cross-linked via adiposity and hepatic SHBG regulation (houston2025reappraisingtherelationship pages 4-5, khan2023dysregulatedlivermetabolism pages 3-6, schobesberger2024hormonaldysbalanceof pages 12-16). - Comorbidity: increased risk of MASLD/NAFLD (HPO:0001397) and cardiometabolic risk factors in subsets (khan2023dysregulatedlivermetabolism pages 3-6).

Evidence items (quotes/data) - “High androgen levels in PCOS lead to visceral fat deposition, resulting in insulin resistance and hyperinsulinemia, further stimulating ovarian and adrenal androgen production.” Current Obesity Reports, 2024; https://doi.org/10.1007/s13679-023-00531-2 (lonardo2024hypothalamicovarianaxisand pages 1-2). - Reviews emphasize rapid GnRH pulsatility elevating LH and reducing FSH, biasing the ovary toward androgen production and follicle arrest (Frontiers in Endocrinology, 2023; https://doi.org/10.3389/fendo.2023.1273542) (wang2023androgenexcessa pages 2-3). - Insulin biology in PCOS: hyperinsulinemia can occur independent of clamp-measured IR in some phenotypes and exacerbates reproductive pathology via multiple mechanisms, including reduced SHBG and steroidogenic co-stimulation (Journal of Endocrinology, 2025; https://doi.org/10.1530/joe-24-0269) (houston2025reappraisingtherelationship pages 4-5). - Developmental expression: PCOS candidate genes (e.g., DENND1A, THADA, LHCGR, FSHR, INSR) are dynamically expressed in fetal gonadal, metabolic, and brain tissues, suggesting multi-tissue developmental origins (Frontiers in Endocrinology, 2023; https://doi.org/10.3389/fendo.2023.1149473) (azumah2023genesinloci pages 13-13). - Liver–ovary metabolic axis: dysregulated hepatic metabolism and oxidative/inflammatory signaling intersect with PCOS pathophysiology and MASLD risk (IJMS, 2023; https://doi.org/10.3390/ijms24087454) (khan2023dysregulatedlivermetabolism pages 3-6). - Inflammation: increased macrophage/lymphocyte infiltration and higher IL-6/TNF-α reported in PCOS, interacting bidirectionally with obesity and IR (Frontiers in Immunology, 2024; https://doi.org/10.3389/fimmu.2024.1470283) (schobesberger2024hormonaldysbalanceof pages 12-16).

Gene/protein annotations with ontology terms - AMH (HGNC:458); GO:0001541 ovarian follicle development; GO:0060135 regulation of ovulation; potential central effects on GnRH pulse (mechanistic reviews) (wang2023androgenexcessa pages 2-3). - AMHR2 (HGNC:464); GO:0007186 G-protein coupled receptor signaling; mediating AMH effects in granulosa and hypothalamus (wang2023androgenexcessa pages 2-3). - CYP17A1 (HGNC:2593); GO:0006702 androgen biosynthetic process; cellular component: endoplasmic reticulum (wang2023androgenexcessa pages 2-3, schobesberger2024hormonaldysbalanceof pages 9-12). - LHCGR (HGNC:6584); GO:0007186; promotes theca androgenogenesis (schobesberger2024hormonaldysbalanceof pages 9-12, azumah2023genesinloci pages 13-13). - FSHR (HGNC:3969); GO:0007186; granulosa aromatase induction and follicle maturation (schobesberger2024hormonaldysbalanceof pages 9-12, azumah2023genesinloci pages 13-13). - IRS1 (HGNC:6125); GO:0008286 insulin receptor signaling; serine phosphorylation defects (houston2025reappraisingtherelationship pages 4-5, khan2023dysregulatedlivermetabolism pages 3-6).

Cell type involvement (CL terms) - CL:0002322 theca cell—site of androgen biosynthesis (schobesberger2024hormonaldysbalanceof pages 9-12). - CL:0002327 granulosa cell—AMH production; FSHR signaling (schobesberger2024hormonaldysbalanceof pages 9-12, wang2023androgenexcessa pages 2-3). - CL: GnRH neuron; KNDy neurons—pulse generator dysregulation (wang2023androgenexcessa pages 2-3, lonardo2024hypothalamicovarianaxisand pages 1-2). - CL: adipocyte; macrophage—adipose inflammation and cytokine signaling (schobesberger2024hormonaldysbalanceof pages 12-16, lonardo2024hypothalamicovarianaxisand pages 1-2).

Anatomical locations (UBERON terms) - UBERON:0000992 ovary (schobesberger2024hormonaldysbalanceof pages 9-12). - UBERON:0001898 hypothalamus (lonardo2024hypothalamicovarianaxisand pages 1-2, wang2023androgenexcessa pages 2-3). - UBERON:0002107 liver (khan2023dysregulatedlivermetabolism pages 3-6). - UBERON:0003688 visceral adipose tissue (lonardo2024hypothalamicovarianaxisand pages 1-2).

Chemical entities (CHEBI) - CHEBI:17347 testosterone (wang2023androgenexcessa pages 2-3, schobesberger2024hormonaldysbalanceof pages 9-12). - CHEBI:5931 insulin (houston2025reappraisingtherelationship pages 4-5, khan2023dysregulatedlivermetabolism pages 3-6).

Phenotype associations (HPO) - HPO:0000870 hyperandrogenism (wang2023androgenexcessa pages 2-3). - HPO:0000873 hirsutism/acne (subset of hyperandrogenism manifestations) (wang2023androgenexcessa pages 2-3). - HPO:0000870 menstrual irregularity/oligo-anovulation (wang2023androgenexcessa pages 2-3, schobesberger2024hormonaldysbalanceof pages 9-12). - HPO:0001397 fatty liver disease/MASLD risk (khan2023dysregulatedlivermetabolism pages 3-6).

Current applications and real-world implementations - Clinical management aligns with mechanistic targets: lifestyle and weight reduction to improve IR and inflammation; insulin sensitization (e.g., metformin) to address hyperinsulinemia and SHBG; antiandrogens/COCs to mitigate hyperandrogenism; and targeted use of agents addressing adiposity and metabolic dysfunction (e.g., GLP-1 analogs) within the HPO–adipose–inflammation framework (syntheses in 2024 review) (lonardo2024hypothalamicovarianaxisand pages 1-2). URL: https://doi.org/10.1007/s13679-023-00531-2

Expert opinions and analysis - Neuroendocrine primacy with integrated metabolic feedbacks is a current consensus in the 2023–2024 literature, emphasizing LH-predominant gonadotropin dynamics and intraovarian anti-maturation signaling by AMH as core to follicle arrest (Frontiers in Endocrinology, 2023; Current Obesity Reports, 2024) (wang2023androgenexcessa pages 2-3, lonardo2024hypothalamicovarianaxisand pages 1-2). - Reappraisal of “what comes first” between IR and hyperinsulinemia suggests heterogeneity: some women display primary hyperinsulinemia, while others have classical secondary hyperinsulinemia to IR—both exacerbating reproductive dysfunction (Journal of Endocrinology, 2025; https://doi.org/10.1530/joe-24-0269) (houston2025reappraisingtherelationship pages 4-5).

Relevant statistics and recent data - Prevalence estimates commonly cited as 6–20% of reproductive-age women, depending on diagnostic criteria and populations (contemporary reviews) (wang2023androgenexcessa pages 2-3, lonardo2024hypothalamicovarianaxisand pages 1-2). URLs: https://doi.org/10.3389/fendo.2023.1273542; https://doi.org/10.1007/s13679-023-00531-2 - Immune signatures: reports of increased macrophage/lymphocyte infiltration and higher IL-6/TNF-α across reproductive and non-reproductive tissues in PCOS, linking inflammation to endocrine/metabolic dysfunction (Frontiers in Immunology, 2024; https://doi.org/10.3389/fimmu.2024.1470283) (schobesberger2024hormonaldysbalanceof pages 12-16). - Hepatic/metabolic comorbidity: detailed molecular links between liver oxidative/inflammatory stress and PCOS metabolic phenotype, supporting MASLD risk (IJMS, 2023; https://doi.org/10.3390/ijms24087454) (khan2023dysregulatedlivermetabolism pages 3-6).

Direct source list with URLs and publication dates - Wang K, Li Y, Chen Y. Androgen excess: a hallmark of PCOS. Frontiers in Endocrinology. Dec 2023. URL: https://doi.org/10.3389/fendo.2023.1273542 (wang2023androgenexcessa pages 2-3). - Lonardo MS, et al. Hypothalamic–ovarian axis and adiposity relationship in PCOS. Current Obesity Reports. Jan 2024. URL: https://doi.org/10.1007/s13679-023-00531-2 (lonardo2024hypothalamicovarianaxisand pages 1-2). - Deng H, et al. Systematic low-grade chronic inflammation in PCOS. Frontiers in Immunology. Dec 2024. URL: https://doi.org/10.3389/fimmu.2024.1470283 (schobesberger2024hormonaldysbalanceof pages 12-16). - Houston EJ, Templeman NM. Reappraising hyperinsulinemia and insulin resistance in PCOS. Journal of Endocrinology. Feb 2025. URL: https://doi.org/10.1530/joe-24-0269 (houston2025reappraisingtherelationship pages 4-5). - Azumah R, et al. PCOS GWAS loci gene expression in fetal tissues. Frontiers in Endocrinology. May 2023. URL: https://doi.org/10.3389/fendo.2023.1149473 (azumah2023genesinloci pages 13-13). - Khan MS, et al. Dysregulated liver metabolism and PCOS. IJMS. Apr 2023. URL: https://doi.org/10.3390/ijms24087454 (khan2023dysregulatedlivermetabolism pages 3-6). - Additional mechanistic overview excerpts on ovarian theca/granulosa dysfunction and neuroendocrine dynamics are synthesized from the same 2023 Frontiers in Endocrinology review and complementing sources listed above (schobesberger2024hormonaldysbalanceof pages 9-12).

Limitations - Causality of gut microbiome in human PCOS remains unresolved due to mixed MR results; experimental FMT data support biological plausibility but are preclinical. Genetic fine-mapping and functional studies (e.g., DENND1A.V2) are rapidly evolving; readers should consult the latest functional genomics for locus-specific mechanisms.

References

(wang2023androgenexcessa pages 2-3): Kexin Wang, Yanhua Li, and Yu Chen. Androgen excess: a hallmark of polycystic ovary syndrome. Frontiers in Endocrinology, Dec 2023. URL: https://doi.org/10.3389/fendo.2023.1273542, doi:10.3389/fendo.2023.1273542. This article has 73 citations and is from a poor quality or predatory journal.
(lonardo2024hypothalamicovarianaxisand pages 1-2): Maria Serena Lonardo, Nunzia Cacciapuoti, Bruna Guida, Mariana Di Lorenzo, Martina Chiurazzi, Simona Damiano, and Ciro Menale. Hypothalamic-ovarian axis and adiposity relationship in polycystic ovary syndrome: physiopathology and therapeutic options for the management of metabolic and inflammatory aspects. Current Obesity Reports, 13:51-70, Jan 2024. URL: https://doi.org/10.1007/s13679-023-00531-2, doi:10.1007/s13679-023-00531-2. This article has 66 citations and is from a peer-reviewed journal.
(schobesberger2024hormonaldysbalanceof pages 9-12): H Schobesberger. Hormonal dysbalance of women with polycystic ovary syndrome and acne. Unknown journal, 2024.
(azumah2023genesinloci pages 13-13): Rafiatu Azumah, Katja Hummitzsch, Richard A. Anderson, and Raymond J. Rodgers. Genes in loci genetically associated with polycystic ovary syndrome are dynamically expressed in human fetal gonadal, metabolic and brain tissues. Frontiers in Endocrinology, May 2023. URL: https://doi.org/10.3389/fendo.2023.1149473, doi:10.3389/fendo.2023.1149473. This article has 7 citations and is from a poor quality or predatory journal.
(houston2025reappraisingtherelationship pages 4-5): Emma Jane Houston and Nicole Meredith Templeman. Reappraising the relationship between hyperinsulinemia and insulin resistance in pcos. The Journal of Endocrinology, Feb 2025. URL: https://doi.org/10.1530/joe-24-0269, doi:10.1530/joe-24-0269. This article has 21 citations.
(khan2023dysregulatedlivermetabolism pages 3-6): Muhammad Sohaib Khan, Hee-Sun Kim, Ranhee Kim, Sang Ho Yoon, and Sang Geon Kim. Dysregulated liver metabolism and polycystic ovarian syndrome. International Journal of Molecular Sciences, 24:7454, Apr 2023. URL: https://doi.org/10.3390/ijms24087454, doi:10.3390/ijms24087454. This article has 17 citations and is from a poor quality or predatory journal.
(schobesberger2024hormonaldysbalanceof pages 12-16): H Schobesberger. Hormonal dysbalance of women with polycystic ovary syndrome and acne. Unknown journal, 2024.

Polycystic Ovary Syndrome

Ask OpenScientist

OpenScientist Report

Classifications

Subtypes

Mechanistic Hypotheses

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Environmental Factors

Biochemical Markers

Source YAML

References & Deep Research

References

Deep Research

Disorder

Key Pathophysiology Nodes

Citation Inventory (for evidence mapping)